ID CAC1C_HUMAN Reviewed; 2221 AA. AC Q13936; B2RUT3; E9PDJ0; Q13917; Q13918; Q13919; Q13920; Q13921; Q13922; AC Q13923; Q13924; Q13925; Q13926; Q13927; Q13928; Q13929; Q13930; Q13932; AC Q13933; Q14743; Q14744; Q15877; Q4VMI7; Q4VMI8; Q4VMI9; Q6PKM7; Q8N6C0; AC Q99025; Q99241; Q99875; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 4. DT 04-NOV-2026, entry version 256. DE RecName: Full=Voltage-dependent L-type calcium channel subunit alpha-1C; DE AltName: Full=Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; DE AltName: Full=Voltage-gated calcium channel subunit alpha Cav1.2; GN Name=CACNA1C; Synonyms=CACH2, CACN2, CACNL1A1, CCHL1A1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), AND RP VARIANTS VAL-1869 AND ARG-1893. RC TISSUE=Fetal fibroblast; RX PubMed=1316612; DOI=10.1073/pnas.89.10.4628; RA Soldatov N.M.; RT "Molecular diversity of L-type Ca2+ channel transcripts in human RT fibroblasts."; RL Proc. Natl. Acad. Sci. U.S.A. 89:4628-4632(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 18 AND 28), NUCLEOTIDE SEQUENCE RP [GENOMIC DNA] OF 1822-1863, FUNCTION (ISOFORM 18), ACTIVITY REGULATION, RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, VARIANT ARG-84, AND TRANSPORTER RP ACTIVITY (ISOFORM 18). RC TISSUE=Heart; RX PubMed=8392192; DOI=10.1073/pnas.90.13.6228; RA Schultz D., Mikala G., Yatani A., Engle D.B., Iles D.E., Segers B., RA Sinke R.J., Weghuis D.O., Kloeckner U., Wakamori M., Wang J.-J., Melvin D., RA Varadi G., Schwartz A.; RT "Cloning, chromosomal localization, and functional expression of the alpha- RT 1 subunit of the L-type voltage-dependent calcium channel from normal human RT heart."; RL Proc. Natl. Acad. Sci. U.S.A. 90:6228-6232(1993). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], NUCLEOTIDE SEQUENCE [MRNA] OF 1112-1803 RP (ISOFORMS 24/27), AND NUCLEOTIDE SEQUENCE [MRNA] OF 1364-1972 (ISOFORMS RP 11/12/19/20/21/22/23/30/31/32). RC TISSUE=Hippocampus, and Lung fibroblast; RX PubMed=7959794; DOI=10.1006/geno.1994.1347; RA Soldatov N.M.; RT "Genomic structure of human L-type Ca2+ channel."; RL Genomics 22:77-87(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 12; 19 AND 20), ALTERNATIVE SPLICING, RP FUNCTION (ISOFORMS 12; 19 AND 20), ACTIVITY REGULATION(ISOFORMS 12; 19 AND RP 20), SUBCELLULAR LOCATION, MUTAGENESIS OF GLY-954 AND TYR-958, AND RP TRANSPORTER ACTIVITY (ISOFORMS 12; 19 AND 20). RC TISSUE=Fibroblast; RX PubMed=7737988; DOI=10.1074/jbc.270.18.10540; RA Soldatov N.M., Bouron A., Reuter H.; RT "Different voltage-dependent inhibition by dihydropyridines of human Ca2+ RT channel splice variants."; RL J. Biol. Chem. 270:10540-10543(1995). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 16 AND 17), ALTERNATIVE RP SPLICING, FUNCTION (ISOFORMS 16 AND 17), SUBCELLULAR LOCATION, VARIANTS RP ARG-84; VAL-1869 AND ARG-1893, AND TRANSPORTER ACTIVITY (ISOFORMS 16 AND RP 17). RC TISSUE=Heart; RX PubMed=9087614; DOI=10.1152/ajpheart.1997.272.3.h1372; RA Kloeckner U., Mikala G., Eisfeld J., Iles D.E., Strobeck M., Mershon J.L., RA Schwartz A., Varadi G.; RT "Properties of three COOH-terminal splice variants of a human cardiac L- RT type Ca2+-channel alpha1-subunit."; RL Am. J. Physiol. 272:H1372-H1381(1997). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 26 AND 27), ALTERNATIVE SPLICING RP (ISOFORMS 9 AND 10), FUNCTION (ISOFORMS 26 AND 27), SUBCELLULAR LOCATION, RP AND TRANSPORTER ACTIVITY (ISOFORMS 26 AND 27). RC TISSUE=Hippocampus; RX PubMed=9013606; DOI=10.1074/jbc.272.6.3560; RA Soldatov N.M., Zuelke R.D., Bouron A., Reuter H.; RT "Molecular structures involved in L-type calcium channel inactivation. Role RT of the carboxyl-terminal region encoded by exons 40-42 in alpha1C subunit RT in the kinetics and Ca2+ dependence of inactivation."; RL J. Biol. Chem. 272:3560-3566(1997). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 21; 22 AND 23), FUNCTION (ISOFORMS 21; RP 22 AND 23), ACTIVITY REGULATION (ISOFORMS 21; 22 AND 23), SUBCELLULAR RP LOCATION, AND TRANSPORTER ACTIVITY (ISOFORMS 21; 22 AND 23). RX PubMed=9607315; DOI=10.1016/s0014-5793(98)00425-6; RA Zuehlke R.D., Bouron A., Soldatov N.M., Reuter H.; RT "Ca2+ channel sensitivity towards the blocker isradipine is affected by RT alternative splicing of the human alpha1C subunit gene."; RL FEBS Lett. 427:220-224(1998). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12), FUNCTION (ISOFORM 12), ACTIVITY RP REGULATION, SUBCELLULAR LOCATION, SUBUNIT, INTERACTION WITH CACNB2, TISSUE RP SPECIFICITY, AND TRANSPORTER ACTIVITY (ISOFORM 12). RC TISSUE=Intestinal smooth muscle; RX PubMed=12176756; DOI=10.1152/ajpcell.00140.2002; RA Lyford G.L., Strege P.R., Shepard A., Ou Y., Ermilov L., Miller S.M., RA Gibbons S.J., Rae J.L., Szurszewski J.H., Farrugia G.; RT "Alpha(1C) (Ca(V)1.2) L-type calcium channel mediates mechanosensitive RT calcium regulation."; RL Am. J. Physiol. 283:C1001-C1008(2002). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 13; 14; 15; 24 AND 25), FUNCTION RP (ISOFORMS 13; 14; 15; 24 AND 25), SUBCELLULAR LOCATION, TISSUE SPECIFICITY, RP AND TRANSPORTER ACTIVITY (ISOFORMS 13; 14; 15; 24 AND 25). RX PubMed=17071743; DOI=10.1073/pnas.0606539103; RA Tiwari S., Zhang Y., Heller J., Abernethy D.R., Soldatov N.M.; RT "Atherosclerosis-related molecular alteration of the human CaV1.2 calcium RT channel alpha1C subunit."; RL Proc. Natl. Acad. Sci. U.S.A. 103:17024-17029(2006). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 11; 28; 29; 30; 31; 32 AND 33), RP ALTERNATIVE SPLICING, AND VARIANTS ARG-84; VAL-1869 AND ARG-1893. RA Soldatov N.; RT "Functional expression of splice variants of human l-type calcium channel RT (isoform 1 gene)."; RL Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 35). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-180 (ISOFORM 34), FUNCTION (ISOFORM 34), RP SUBCELLULAR LOCATION, SUBUNIT, INTERACTION WITH CACNB2, AND TRANSPORTER RP ACTIVITY (ISOFORM 34). RX PubMed=11741969; DOI=10.1074/jbc.c100642200; RA Blumenstein Y., Kanevsky N., Sahar G., Barzilai R., Ivanina T., Dascal N.; RT "A novel long N-terminal isoform of human L-type Ca2+ channel is up- RT regulated by protein kinase C."; RL J. Biol. Chem. 277:3419-3423(2002). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1182-1503 (ISOFORMS 6/12/20/23/24), AND RP NUCLEOTIDE SEQUENCE [MRNA] OF 1182-1503 (ISOFORMS 7/13/16/17/18/21/22). RC TISSUE=Heart; RX PubMed=2173707; DOI=10.1016/s0021-9258(17)30522-7; RA Perez-Reyes E., Wei X., Castellano A., Birnbaumer L.; RT "Molecular diversity of L-type calcium channels. Evidence for alternative RT splicing of the transcripts of three non-allelic genes."; RL J. Biol. Chem. 265:20430-20436(1990). RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1140-1206. RC TISSUE=Heart; RX PubMed=1653763; DOI=10.1016/0888-7543(91)90471-p; RA Powers P.A., Gregg R.G., Lalley P.A., Liao M., Hogan K.; RT "Assignment of the human gene for the alpha 1 subunit of the cardiac DHP- RT sensitive Ca2+ channel (CCHL1A1) to chromosome 12p12-pter."; RL Genomics 10:835-839(1991). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1196-1421. RC TISSUE=Brain; RX PubMed=1335957; DOI=10.1016/s0888-7543(05)80135-1; RA Sun W., McPherson J.D., Hoang D.Q., Wasmuth J.J., Evans G.A., Montal M.; RT "Mapping of a human brain voltage-gated calcium channel to human chromosome RT 12p13-pter."; RL Genomics 14:1092-1094(1992). RN [17] RP FUNCTION, SUBCELLULAR LOCATION, ACTIVITY REGULATION, MUTAGENESIS OF RP GLU-363; GLU-1135 AND GLU-1464, CALCIUM-BINDING, SITE, TRANSPORTER RP ACTIVITY, AND CHARACTERIZATION OF VARIANT TS LYS-1135. RX PubMed=8099908; DOI=10.1016/s0021-9258(19)38613-2; RA Tang S., Mikala G., Bahinski A., Yatani A., Varadi G., Schwartz A.; RT "Molecular localization of ion selectivity sites within the pore of a human RT L-type cardiac calcium channel."; RL J. Biol. Chem. 268:13026-13029(1993). RN [18] RP INTERACTION WITH CACNA2D4, IDENTIFICATION IN A COMPLEX WITH CACNB3 AND RP CACNA2D4, SUBUNIT, FUNCTION, SUBCELLULAR LOCATION, AND TRANSPORTER RP ACTIVITY. RX PubMed=12181424; DOI=10.1124/mol.62.3.485; RA Qin N., Yagel S., Momplaisir M.-L., Codd E.E., D'Andrea M.R.; RT "Molecular cloning and characterization of the human voltage-gated calcium RT channel alpha(2)delta-4 subunit."; RL Mol. Pharmacol. 62:485-496(2002). RN [19] RP INTERACTION WITH CABP1. RX PubMed=15140941; DOI=10.1523/jneurosci.5523-03.2004; RA Zhou H., Kim S.-A., Kirk E.A., Tippens A.L., Sun H., Haeseleer F., Lee A.; RT "Ca2+-binding protein-1 facilitates and forms a postsynaptic complex with RT Cav1.2 (L-type) Ca2+ channels."; RL J. Neurosci. 24:4698-4708(2004). RN [20] RP INTERACTION WITH CABP1. RX PubMed=15980432; DOI=10.1074/jbc.m504167200; RA Zhou H., Yu K., McCoy K.L., Lee A.; RT "Molecular mechanism for divergent regulation of Cav1.2 Ca2+ channels by RT calmodulin and Ca2+-binding protein-1."; RL J. Biol. Chem. 280:29612-29619(2005). RN [21] RP FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, SUBUNIT, INTERACTION RP WITH STAC2 AND STAC3, AND TRANSPORTER ACTIVITY. RX PubMed=29078335; DOI=10.1073/pnas.1708852114; RA Wong King Yuen S.M., Campiglio M., Tung C.C., Flucher B.E., Van Petegem F.; RT "Structural insights into binding of STAC proteins to voltage-gated calcium RT channels."; RL Proc. Natl. Acad. Sci. U.S.A. 114:E9520-E9528(2017). RN [22] RP PHOSPHORYLATION AT SER-1981 BY PKA, FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=28119464; DOI=10.1126/scisignal.aaf9647; RA Nystoriak M.A., Nieves-Cintron M., Patriarchi T., Buonarati O.R., RA Prada M.P., Morotti S., Grandi E., Fernandes J.D., Forbush K., Hofmann F., RA Sasse K.C., Scott J.D., Ward S.M., Hell J.W., Navedo M.F.; RT "Ser1928 phosphorylation by PKA stimulates the L-type Ca2+ channel CaV1.2 RT and vasoconstriction during acute hyperglycemia and diabetes."; RL Sci. Signal. 10:0-0(2017). RN [23] RP FUNCTION, ACTIVITY REGULATION, ALTERNATIVE SPLICING, INTERACTION WITH RP CALM1; CACNA2D1; CACNB2 AND CACNB3, SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=29742403; DOI=10.1016/j.bpj.2018.03.029; RA Bartels P., Yu D., Huang H., Hu Z., Herzig S., Soong T.W.; RT "Alternative Splicing at N Terminus and Domain I Modulates CaV1.2 RT Inactivation and Surface Expression."; RL Biophys. J. 114:2095-2106(2018). RN [24] RP FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH INFLUENZAVIRUS H1 RP HEMAGGLUTININ (MICROBIAL INFECTION). RX PubMed=29779930; DOI=10.1016/j.chom.2018.04.015; RA Fujioka Y., Nishide S., Ose T., Suzuki T., Kato I., Fukuhara H., RA Fujioka M., Horiuchi K., Satoh A.O., Nepal P., Kashiwagi S., Wang J., RA Horiguchi M., Sato Y., Paudel S., Nanbo A., Miyazaki T., Hasegawa H., RA Maenaka K., Ohba Y.; RT "Channel Binds Hemagglutinin and Mediates Influenza A Virus Entry into RT Mammalian Cells."; RL Cell Host Microbe 23:809-818(2018). RN [25] RP X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH CACNB2. RX PubMed=15141227; DOI=10.1038/nature02588; RA Van Petegem F., Clark K.A., Chatelain F.C., Minor D.L. Jr.; RT "Structure of a complex between a voltage-gated calcium channel beta- RT subunit and an alpha-subunit domain."; RL Nature 429:671-675(2004). RN [26] {ECO:0007744|PDB:2BE6} RP X-RAY CRYSTALLOGRAPHY, FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RP CALM1, MUTAGENESIS OF 1666-PHE--PHE-1670 AND ILE-1672, AND TRANSPORTER RP ACTIVITY. RX PubMed=16299511; DOI=10.1038/nsmb1027; RA Van Petegem F., Chatelain F.C., Minor D.L. Jr.; RT "Insights into voltage-gated calcium channel regulation from the structure RT of the CaV1.2 IQ domain-Ca2+/calmodulin complex."; RL Nat. Struct. Mol. Biol. 12:1108-1115(2005). RN [27] {ECO:0007744|PDB:2F3Z} RP X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH CALM1. RX PubMed=16338416; DOI=10.1016/j.str.2005.09.021; RA Fallon J.L., Halling D.B., Hamilton S.L., Quiocho F.A.; RT "Structure of calmodulin bound to the hydrophobic IQ domain of the cardiac RT Ca(v)1.2 calcium channel."; RL Structure 13:1881-1886(2005). RN [28] {ECO:0007744|PDB:3G43} RP X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH CALM1. RX PubMed=19279214; DOI=10.1073/pnas.0807487106; RA Fallon J.L., Baker M.R., Xiong L., Loy R.E., Yang G., Dirksen R.T., RA Hamilton S.L., Quiocho F.A.; RT "Crystal structure of dimeric cardiac L-type calcium channel regulatory RT domains bridged by Ca2+* calmodulins."; RL Proc. Natl. Acad. Sci. U.S.A. 106:5135-5140(2009). RN [29] {ECO:0007744|PDB:3OXQ} RP X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH CALM1, FUNCTION, SUBCELLULAR RP LOCATION, SUBUNIT, INTERACTION WITH CACNB2 AND CACNA2D1, MUTAGENESIS OF RP LEU-1610, AND TRANSPORTER ACTIVITY. RX PubMed=20953164; DOI=10.1038/emboj.2010.260; RA Kim E.Y., Rumpf C.H., Van Petegem F., Arant R.J., Findeisen F., RA Cooley E.S., Isacoff E.Y., Minor D.L. Jr.; RT "Multiple C-terminal tail Ca(2+)/CaMs regulate Ca(V)1.2 function but do not RT mediate channel dimerization."; RL EMBO J. 29:3924-3938(2010). RN [30] {ECO:0007744|PDB:2LQC} RP STRUCTURE BY NMR OF 47-68 IN COMPLEX WITH CALMODULIN, AND INTERACTION WITH RP CALM1. RX PubMed=22518098; DOI=10.3389/fnmol.2012.00038; RA Liu Z., Vogel H.J.; RT "Structural basis for the regulation of L-type voltage-gated calcium RT channels: interactions between the N-terminal cytoplasmic domain and RT Ca(2+)-calmodulin."; RL Front. Mol. Neurosci. 5:38-38(2012). RN [31] {ECO:0007744|PDB:8FHS, ECO:0007744|PDB:8WE6, ECO:0007744|PDB:8WE7, ECO:0007744|PDB:8WE8, ECO:0007744|PDB:8WE9, ECO:0007744|PDB:8WEA} RP STRUCTURE BY ELECTRON MICROSCOPY IN APO AND IN COMPLEX WITH CHEMICAL DRUGS RP AND SNAKE TOXIN CALCISEPTINE (ISOFORM 4), DISULFIDE BONDS, GLYCOSYLATION AT RP ASN-1436, AND ACTIVITY REGULATION. RX PubMed=37972591; DOI=10.1016/j.cell.2023.10.007; RA Gao S., Yao X., Chen J., Huang G., Fan X., Xue L., Li Z., Wu T., Zheng Y., RA Huang J., Jin X., Wang Y., Wang Z., Yu Y., Liu L., Pan X., Song C., Yan N.; RT "Structural basis for human Cav1.2 inhibition by multiple drugs and the RT neurotoxin calciseptine."; RL Cell 186:5363-5374.e16(2023). RN [32] RP VARIANT TS ARG-406, CHARACTERIZATION OF VARIANT TS ARG-406, FUNCTION, RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND TRANSPORTER ACTIVITY. RX PubMed=15454078; DOI=10.1016/j.cell.2004.09.011; RA Splawski I., Timothy K.W., Sharpe L.M., Decher N., Kumar P., Bloise R., RA Napolitano C., Schwartz P.J., Joseph R.M., Condouris K., Tager-Flusberg H., RA Priori S.G., Sanguinetti M.C., Keating M.T.; RT "Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder RT including arrhythmia and autism."; RL Cell 119:19-31(2004). RN [33] RP VARIANT TS SER-402, FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CACNB2 RP AND CACNA2D1, SUBUNIT, AND TRANSPORTER ACTIVITY. RX PubMed=15863612; DOI=10.1073/pnas.0502506102; RA Splawski I., Timothy K.W., Decher N., Kumar P., Sachse F.B., Beggs A.H., RA Sanguinetti M.C., Keating M.T.; RT "Severe arrhythmia disorder caused by cardiac L-type calcium channel RT mutations."; RL Proc. Natl. Acad. Sci. U.S.A. 102:8089-8096(2005). RN [34] RP VARIANTS BRGDA3 VAL-39 AND ARG-490, CHARACTERIZATION OF VARIANTS BRGDA3 RP VAL-39 AND ARG-490, FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RP CACNB2, SUBUNIT, AND TRANSPORTER ACTIVITY. RX PubMed=17224476; DOI=10.1161/circulationaha.106.668392; RA Antzelevitch C., Pollevick G.D., Cordeiro J.M., Casis O., Sanguinetti M.C., RA Aizawa Y., Guerchicoff A., Pfeiffer R., Oliva A., Wollnik B., Gelber P., RA Bonaros E.P. Jr., Burashnikov E., Wu Y., Sargent J.D., Schickel S., RA Oberheiden R., Bhatia A., Hsu L.F., Haissaguerre M., Schimpf R., RA Borggrefe M., Wolpert C.; RT "Loss-of-function mutations in the cardiac calcium channel underlie a new RT clinical entity characterized by ST-segment elevation, short QT intervals, RT and sudden cardiac death."; RL Circulation 115:442-449(2007). RN [35] RP VARIANTS BRGDA3 VAL-39; ARG-490; LYS-1135; GLU-GLU-THR-SER-GLN-1916 INS; RP CYS-1920; GLN-1963; ILE-2097 AND ASN-2213, CHARACTERIZATION OF VARIANT RP BRGDA3 ILE-2097, AND VARIANTS ARG-37; SER-817; GLU-850 DEL; GLY-1765; RP MET-1835 AND GLN-2056. RX PubMed=20817017; DOI=10.1016/j.hrthm.2010.08.026; RA Burashnikov E., Pfeiffer R., Barajas-Martinez H., Delpon E., Hu D., RA Desai M., Borggrefe M., Haeissaguerre M., Kanter R., Pollevick G.D., RA Guerchicoff A., Laino R., Marieb M., Nademanee K., Nam G.B., Robles R., RA Schimpf R., Stapleton D.D., Viskin S., Winters S., Wolpert C., Zimmern S., RA Veltmann C., Antzelevitch C.; RT "Mutations in the cardiac L-type calcium channel associated with inherited RT J-wave syndromes and sudden cardiac death."; RL Heart Rhythm 7:1872-1882(2010). RN [36] RP VARIANT ARG-878. RX PubMed=21248752; DOI=10.1038/nature09639; RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J., RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K., RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.; RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene RT PBRM1 in renal carcinoma."; RL Nature 469:539-542(2011). RN [37] RP VARIANTS LQT8 GLU-834; ARG-857; LEU-857 AND GLN-1989, CHARACTERIZATION OF RP VARIANT LQT8 ARG-857, FUNCTION, INVOLVEMENT IN LQT8, AND TRANSPORTER RP ACTIVITY. RX PubMed=23677916; DOI=10.1161/circgenetics.113.000138; RA Boczek N.J., Best J.M., Tester D.J., Giudicessi J.R., Middha S., RA Evans J.M., Kamp T.J., Ackerman M.J.; RT "Exome sequencing and systems biology converge to identify novel mutations RT in the L-type calcium channel, CACNA1C, linked to autosomal dominant long RT QT syndrome."; RL Circ. Cardiovasc. Genet. 6:279-289(2013). RN [38] RP VARIANTS LQT8 SER-381; ILE-456; ASP-582; HIS-858 AND CYS-1831, RP CHARACTERIZATION OF VARIANTS LQT8 SER-381; ILE-456; ASP-582; HIS-858 AND RP CYS-1831, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, INTERACTION WITH CACNB2 RP AND CACNA2D1, AND TRANSPORTER ACTIVITY. RX PubMed=24728418; DOI=10.1093/europace/euu063; RA Fukuyama M., Wang Q., Kato K., Ohno S., Ding W.G., Toyoda F., Itoh H., RA Kimura H., Makiyama T., Ito M., Matsuura H., Horie M.; RT "Long QT syndrome type 8: novel CACNA1C mutations causing QT prolongation RT and variant phenotypes."; RL Europace 16:1828-1837(2014). RN [39] RP VARIANTS TS CYS-518 AND HIS-518, CHARACTERIZATION OF VARIANTS TS CYS-518 RP AND HIS-518, FUNCTION, SUBCELLULAR LOCATION, AND TRANSPORTER ACTIVITY. RX PubMed=26253506; DOI=10.1161/circep.115.002745; RA Boczek N.J., Ye D., Jin F., Tester D.J., Huseby A., Bos J.M., Johnson A.J., RA Kanter R., Ackerman M.J.; RT "Identification and functional characterization of a novel CACNA1C-mediated RT cardiac disorder characterized by prolonged QT intervals with hypertrophic RT cardiomyopathy, congenital heart defects, and sudden cardiac death."; RL Circ. Arrhythm. Electrophysiol. 8:1122-1132(2015). RN [40] RP VARIANT TS THR-1186, CHARACTERIZATION OF VARIANT TS THR-1186, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=25260352; DOI=10.1016/j.hrthm.2014.09.051; RA Boczek N.J., Miller E.M., Ye D., Nesterenko V.V., Tester D.J., RA Antzelevitch C., Czosek R.J., Ackerman M.J., Ware S.M.; RT "Novel Timothy syndrome mutation leading to increase in CACNA1C window RT current."; RL Heart Rhythm 12:211-219(2015). RN [41] RP VARIANTS LQT8 THR-28; LYS-477; GLY-860; THR-1186; VAL-1186; THR-1365; RP MET-1523; LYS-1544; ASN-1787; ILE-1800; LYS-1948; MET-1953; ASN-2081; RP ILE-2097 AND GLY-2122, CHARACTERIZATION OF VARIANTS LQT8 THR-28; GLY-860; RP THR-1186; VAL-1186; MET-1523 AND LYS-1544, VARIANTS ARG-37; THR-304; RP SER-817; ILE-1755; GLY-1765; MET-1835; ARG-1843; CYS-1972; GLN-2056 AND RP SER-2174, FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=25633834; DOI=10.1016/j.yjmcc.2015.01.002; RA Wemhoener K., Friedrich C., Stallmeyer B., Coffey A.J., Grace A., RA Zumhagen S., Seebohm G., Ortiz-Bonnin B., Rinne S., Sachse F.B., RA Schulze-Bahr E., Decher N.; RT "Gain-of-function mutations in the calcium channel CACNA1C (Cav1.2) cause RT non-syndromic long-QT but not Timothy syndrome."; RL J. Mol. Cell. Cardiol. 80:186-195(2015). RN [42] RP VARIANT HIS-1159. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [43] RP VARIANTS GLU-850 DEL AND SER-2091, CHARACTERIZATION OF VARIANTS GLU-850 DEL RP AND SER-2091, FUNCTION, SUBCELLULAR LOCATION, AND TRANSPORTER ACTIVITY. RX PubMed=27218670; DOI=10.1111/chd.12371; RA Sutphin B.S., Boczek N.J., Barajas-Martinez H., Hu D., Ye D., Tester D.J., RA Antzelevitch C., Ackerman M.J.; RT "Molecular and functional characterization of rare CACNA1C variants in RT sudden unexplained death in the young."; RL Congenit. Heart Dis. 11:683-692(2016). RN [44] RP INVOLVEMENT IN NEDHLSS, AND VARIANT NEDHLSS MET-1411. RX PubMed=30513141; DOI=10.1002/ajmg.a.40657; RA Bozarth X., Dines J.N., Cong Q., Mirzaa G.M., Foss K., RA Lawrence Merritt J. II, Thies J., Mefford H.C., Novotny E.; RT "Expanding clinical phenotype in CACNA1C related disorders: From neonatal RT onset severe epileptic encephalopathy to late-onset epilepsy."; RL Am. J. Med. Genet. A 176:2733-2739(2018). RN [45] RP VARIANT TS PHE-643, CHARACTERIZATION OF VARIANT TS PHE-643, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=30023270; DOI=10.1016/j.hrcr.2018.03.003; RA Ozawa J., Ohno S., Saito H., Saitoh A., Matsuura H., Horie M.; RT "A novel CACNA1C mutation identified in a patient with Timothy syndrome RT without syndactyly exerts both marked loss- and gain-of-function effects."; RL HeartRhythm Case Rep. 4:273-277(2018). RN [46] RP VARIANT TS CYS-518, CHARACTERIZATION OF VARIANT TS CYS-518, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=31430211; DOI=10.1161/circgen.119.002534; RA Estes S.I., Ye D., Zhou W., Dotzler S.M., Tester D.J., Bos J.M., RA Kim C.S.J., Ackerman M.J.; RT "Characterization of the CACNA1C-R518C Missense Mutation in the RT Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell RT Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium RT Channel Perturbation."; RL Circ. Genom. Precis. Med. 12:e002534-e002534(2019). RN [47] RP VARIANT TS LYS-1135, CHARACTERIZATION OF VARIANT TS LYS-1135, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=30172029; DOI=10.1016/j.hrthm.2018.08.030; RA Ye D., Tester D.J., Zhou W., Papagiannis J., Ackerman M.J.; RT "A pore-localizing CACNA1C-E1115K missense mutation, identified in a RT patient with idiopathic QT prolongation, bradycardia, and autism spectrum RT disorder, converts the L-type calcium channel into a hybrid nonselective RT monovalent cation channel."; RL Heart Rhythm 16:270-278(2019). RN [48] RP VARIANT LQT8 HIS-858. RX PubMed=30345660; DOI=10.1002/mgg3.476; RA Gardner R.J.M., Crozier I.G., Binfield A.L., Love D.R., Lehnert K., RA Gibson K., Lintott C.J., Snell R.G., Jacobsen J.C., Jones P.P., RA Waddell-Smith K.E., Kennedy M.A., Skinner J.R.; RT "Penetrance and expressivity of the R858H CACNA1C variant in a five- RT generation pedigree segregating an arrhythmogenic channelopathy."; RL Mol. Genet. Genomic Med. 7:E00476-E00476(2019). RN [49] RP VARIANTS NEDHLSS 161-ARG--LEU-2221 DEL; LEU-166; ARG-177; TRP-324; MET-403; RP 528-TRP--LEU-2221 DEL; ARG-601; THR-611; ARG-614; PRO-614; PHE-657; ILE-743 RP DEL; ALA-1187; VAL-1408; LEU-1411 AND 1989-ARG--LEU-2221 DEL, RP CHARACTERIZATION OF VARIANT NEDHLSS VAL-1408, FUNCTION, AND TRANSPORTER RP ACTIVITY. RX PubMed=34163037; DOI=10.1038/s41436-021-01232-8; RG Undiagnosed Diseases Network; RA Rodan L.H., Spillmann R.C., Kurata H.T., Lamothe S.M., Maghera J., RA Jamra R.A., Alkelai A., Antonarakis S.E., Atallah I., Bar-Yosef O., RA Bilan F., Bjorgo K., Blanc X., Van Bogaert P., Bolkier Y., Burrage L.C., RA Christ B.U., Granadillo J.L., Dickson P., Donald K.A., Dubourg C., RA Eliyahu A., Emrick L., Engleman K., Gonfiantini M.V., Good J.M., Kalser J., RA Kloeckner C., Lachmeijer G., Macchiaiolo M., Nicita F., Odent S., RA O'Heir E., Ortiz-Gonzalez X., Pacio-Miguez M., Palomares-Bralo M., Pena L., RA Platzer K., Quinodoz M., Ranza E., Rosenfeld J.A., Roulet-Perez E., RA Santani A., Santos-Simarro F., Pode-Shakked B., Skraban C., Slaugh R., RA Superti-Furga A., Thiffault I., van Jaabrsveld R.H., Vincent M., Wang H.G., RA Zacher P., Rush E., Pitt G.S., Au P.Y.B., Shashi V.; RT "Phenotypic expansion of CACNA1C-associated disorders to include isolated RT neurological manifestations."; RL Genet. Med. 23:1922-1932(2021). RN [50] RP ERRATUM OF PUBMED:34163037. RX PubMed=34522029; DOI=10.1038/s41436-021-01306-7; RG Undiagnosed Diseases Network; RA Rodan L.H., Spillmann R.C., Kurata H.T., Lamothe S.M., Maghera J., RA Jamra R.A., Alkelai A., Antonarakis S.E., Atallah I., Bar-Yosef O., RA Bilan F., Bjorgo K., Blanc X., Van Bogaert P., Bolkier Y., Burrage L.C., RA Christ B.U., Granadillo J.L., Dickson P., Donald K.A., Dubourg C., RA Eliyahu A., Emrick L., Engleman K., Gonfiantini M.V., Good J.M., Kalser J., RA Kloeckner C., Lachmeijer G., Macchiaiolo M., Nicita F., Odent S., RA O'Heir E., Ortiz-Gonzalez X., Pacio-Miguez M., Palomares-Bralo M., Pena L., RA Platzer K., Quinodoz M., Ranza E., Rosenfeld J.A., Roulet-Perez E., RA Santani A., Santos-Simarro F., Pode-Shakked B., Skraban C., Slaugh R., RA Superti-Furga A., Thiffault I., van Jaabrsveld R.H., Vincent M., Wang H.G., RA Zacher P., Rush E., Pitt G.S., Au P.Y.B., Shashi V.; RL Genet. Med. 23:2016-2016(2021). CC -!- FUNCTION: Pore-forming, alpha-1C subunit of the voltage-gated calcium CC channel that gives rise to L-type calcium currents (PubMed:12181424, CC PubMed:15454078, PubMed:15863612, PubMed:16299511, PubMed:17224476, CC PubMed:20953164, PubMed:23677916, PubMed:24728418, PubMed:26253506, CC PubMed:27218670, PubMed:29078335, PubMed:29742403, PubMed:30023270, CC PubMed:30172029, PubMed:34163037, PubMed:8099908). Mediates influx of CC calcium ions into the cytoplasm, and thereby triggers calcium release CC from the sarcoplasm (By similarity). Plays an important role in CC excitation-contraction coupling in the heart. Required for normal heart CC development and normal regulation of heart rhythm (PubMed:15454078, CC PubMed:15863612, PubMed:17224476, PubMed:24728418, PubMed:26253506). CC Required for normal contraction of smooth muscle cells in blood vessels CC and in the intestine. Essential for normal blood pressure regulation CC via its role in the contraction of arterial smooth muscle cells CC (PubMed:28119464). Long-lasting (L-type) calcium channels belong to the CC 'high-voltage activated' (HVA) group (Probable). CC {ECO:0000250|UniProtKB:P15381, ECO:0000269|PubMed:12181424, CC ECO:0000269|PubMed:15454078, ECO:0000269|PubMed:15863612, CC ECO:0000269|PubMed:16299511, ECO:0000269|PubMed:17224476, CC ECO:0000269|PubMed:20953164, ECO:0000269|PubMed:23677916, CC ECO:0000269|PubMed:24728418, ECO:0000269|PubMed:25260352, CC ECO:0000269|PubMed:25633834, ECO:0000269|PubMed:26253506, CC ECO:0000269|PubMed:27218670, ECO:0000269|PubMed:28119464, CC ECO:0000269|PubMed:29078335, ECO:0000269|PubMed:29742403, CC ECO:0000269|PubMed:30023270, ECO:0000269|PubMed:30172029, CC ECO:0000269|PubMed:31430211, ECO:0000269|PubMed:34163037, CC ECO:0000269|PubMed:8099908, ECO:0000305}. CC -!- FUNCTION: [Isoform 12]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:12176756, ECO:0000269|PubMed:7737988}. CC -!- FUNCTION: [Isoform 13]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:17071743}. CC -!- FUNCTION: [Isoform 14]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:17071743}. CC -!- FUNCTION: [Isoform 15]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:17071743}. CC -!- FUNCTION: [Isoform 16]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:9087614}. CC -!- FUNCTION: [Isoform 17]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:9087614}. CC -!- FUNCTION: [Isoform 18]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:8392192}. CC -!- FUNCTION: [Isoform 19]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:7737988}. CC -!- FUNCTION: [Isoform 20]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:7737988}. CC -!- FUNCTION: [Isoform 21]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:9607315}. CC -!- FUNCTION: [Isoform 22]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:9607315}. CC -!- FUNCTION: [Isoform 23]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:9607315}. CC -!- FUNCTION: [Isoform 24]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:17071743}. CC -!- FUNCTION: [Isoform 25]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:17071743}. CC -!- FUNCTION: [Isoform 26]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:9013606}. CC -!- FUNCTION: [Isoform 27]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:9013606}. CC -!- FUNCTION: [Isoform 34]: Pore-forming, alpha-1C subunit of the voltage- CC gated calcium channel that gives rise to L-type calcium currents. CC {ECO:0000269|PubMed:11741969}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for Influenzavirus CC (PubMed:29779930). May play a critical role in allowing virus entry CC when sialylated and expressed on lung tissues (PubMed:29779930). CC {ECO:0000269|PubMed:29779930}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:12181424, CC ECO:0000269|PubMed:15454078, ECO:0000269|PubMed:15863612, CC ECO:0000269|PubMed:16299511, ECO:0000269|PubMed:17224476, CC ECO:0000269|PubMed:20953164, ECO:0000269|PubMed:23677916, CC ECO:0000269|PubMed:24728418, ECO:0000269|PubMed:25260352, CC ECO:0000269|PubMed:25633834, ECO:0000269|PubMed:26253506, CC ECO:0000269|PubMed:27218670, ECO:0000269|PubMed:28119464, CC ECO:0000269|PubMed:29078335, ECO:0000269|PubMed:30023270, CC ECO:0000269|PubMed:30172029, ECO:0000269|PubMed:31430211, CC ECO:0000269|PubMed:34163037, ECO:0000269|PubMed:8099908}; CC -!- CATALYTIC ACTIVITY: [Isoform 12]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:12176756, CC ECO:0000269|PubMed:7737988}; CC -!- CATALYTIC ACTIVITY: [Isoform 13]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:17071743}; CC -!- CATALYTIC ACTIVITY: [Isoform 14]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:17071743}; CC -!- CATALYTIC ACTIVITY: [Isoform 15]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:17071743}; CC -!- CATALYTIC ACTIVITY: [Isoform 16]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:9087614}; CC -!- CATALYTIC ACTIVITY: [Isoform 17]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:9087614}; CC -!- CATALYTIC ACTIVITY: [Isoform 18]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:8392192}; CC -!- CATALYTIC ACTIVITY: [Isoform 19]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:7737988}; CC -!- CATALYTIC ACTIVITY: [Isoform 20]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:7737988}; CC -!- CATALYTIC ACTIVITY: [Isoform 21]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:9607315}; CC -!- CATALYTIC ACTIVITY: [Isoform 22]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:9607315}; CC -!- CATALYTIC ACTIVITY: [Isoform 23]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:9607315}; CC -!- CATALYTIC ACTIVITY: [Isoform 24]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:17071743}; CC -!- CATALYTIC ACTIVITY: [Isoform 25]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:17071743}; CC -!- CATALYTIC ACTIVITY: [Isoform 26]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:9013606}; CC -!- CATALYTIC ACTIVITY: [Isoform 27]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:9013606}; CC -!- CATALYTIC ACTIVITY: [Isoform 34]: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11741969}; CC -!- ACTIVITY REGULATION: Inhibited by dihydropyridines (DHP), such as CC isradipine (PubMed:7737988, PubMed:8099908, PubMed:8392192, CC PubMed:9607315). Inhibited by nifedipine (By similarity). Selectively CC inhibited by the snake venom calciseptine (PubMed:37972591). Inhibited CC by pinaverium bromide (PIN) (PubMed:37972591). Channel activity is CC regulated by Ca(2+) and calmodulin (Probable) (PubMed:29742403). CC Binding of STAC1, STAC2 or STAC3 to a region that overlaps with the CC calmodulin binding site inhibits channel inactivation by Ca(2+) and CC calmodulin (PubMed:29078335). Binding of calmodulin or CABP1 at the CC same regulatory sites results in opposite effects on the channel CC function (PubMed:15140941, PubMed:15980432). Shear stress and pressure CC increases calcium channel activity (PubMed:12176756). CC {ECO:0000250|UniProtKB:P15381, ECO:0000269|PubMed:12176756, CC ECO:0000269|PubMed:15140941, ECO:0000269|PubMed:15980432, CC ECO:0000269|PubMed:29078335, ECO:0000269|PubMed:29742403, CC ECO:0000269|PubMed:7737988, ECO:0000269|PubMed:8099908, CC ECO:0000269|PubMed:8392192, ECO:0000269|PubMed:9607315, CC ECO:0000305|PubMed:16299511}. CC -!- SUBUNIT: Component of a calcium channel complex consisting of a pore- CC forming alpha subunit (CACNA1C) and ancillary beta, gamma and delta CC subunits (PubMed:12176756, PubMed:12181424, PubMed:15141227, CC PubMed:16299511, PubMed:20953164, PubMed:29078335, PubMed:29742403). CC The channel complex contains alpha, beta, gamma and delta subunits in a CC 1:1:1:1 ratio, i.e. it contains only one of each type of subunit CC (Probable). CACNA1C channel activity is modulated by ancillary CC subunits, such as CACNB1, CACNB2, CACNB3, CACNA2D1 and CACNA2D4 CC (PubMed:11741969, PubMed:12181424, PubMed:17224476, PubMed:29742403). CC Interacts with the gamma subunits CACNG4, CACNG6, CACNG7 and CACNG8 (By CC similarity). Interacts with CACNB1 (By similarity). Interacts with CC CACNB2 (PubMed:11741969, PubMed:12176756, PubMed:15141227, CC PubMed:15863612, PubMed:17224476, PubMed:20953164, PubMed:24728418, CC PubMed:29742403). Identified in a complex with CACNA2D4 and CACNB3 CC (PubMed:12181424). Interacts with CACNB3 (PubMed:12181424, CC PubMed:29742403). Interacts with CACNA2D1 (PubMed:15863612, CC PubMed:20953164, PubMed:24728418, PubMed:29742403). Interacts with CC CACNA2D4 (PubMed:12181424). Interacts with CALM1 (PubMed:16299511, CC PubMed:16338416, PubMed:19279214, PubMed:20953164, PubMed:22518098, CC PubMed:29742403). Interacts (via the N-terminus and the C-terminal C CC and IQ motifs) with CABP1; this inhibits Ca(2+)-dependent channel CC inactivation (PubMed:15140941, PubMed:15980432). The binding via the C CC motif is calcium independent whereas the binding via IQ requires the CC presence of calcium and is mutually exclusive with calmodulin binding CC (PubMed:15140941). The binding to the cytoplasmic N-terminal domain is CC calcium independent but is essential for the channel modulation. CC Interacts (via C-terminal CDB motif) with CABP5; in a calcium-dependent CC manner (By similarity). Interacts with CIB1; the interaction increases CC upon cardiomyocytes hypertrophy (By similarity). Interacts with STAC2 CC and STAC3; this inhibits channel inactivation (PubMed:29078335). CC Interacts (via N-terminus) with LRRC7; in neurons, the interaction CC enhances channel trafficking to the dendritic cell membrane and CC increases channel postsynaptic clustering, thereby facilitating CC excitatory calcium signaling (By similarity). CC {ECO:0000250|UniProtKB:P15381, ECO:0000250|UniProtKB:Q01815, CC ECO:0000269|PubMed:11741969, ECO:0000269|PubMed:12176756, CC ECO:0000269|PubMed:12181424, ECO:0000269|PubMed:15140941, CC ECO:0000269|PubMed:15141227, ECO:0000269|PubMed:15863612, CC ECO:0000269|PubMed:15980432, ECO:0000269|PubMed:16299511, CC ECO:0000269|PubMed:16338416, ECO:0000269|PubMed:17224476, CC ECO:0000269|PubMed:19279214, ECO:0000269|PubMed:20953164, CC ECO:0000269|PubMed:22518098, ECO:0000269|PubMed:24728418, CC ECO:0000269|PubMed:29078335, ECO:0000269|PubMed:29742403, ECO:0000305}. CC -!- SUBUNIT: (Microbial infection) Interacts with influenzavirus H1 CC hemagglutinin. {ECO:0000269|PubMed:29779930}. CC -!- INTERACTION: CC Q13936; P12814: ACTN1; NbExp=2; IntAct=EBI-1038838, EBI-351710; CC Q13936; Q06481: APLP2; NbExp=5; IntAct=EBI-1038838, EBI-79306; CC Q13936; P01024: C3; NbExp=2; IntAct=EBI-1038838, EBI-905851; CC Q13936; Q9NZU7: CABP1; NbExp=4; IntAct=EBI-1038838, EBI-907894; CC Q13936; Q02641-1: CACNB1; NbExp=2; IntAct=EBI-1038838, EBI-15707950; CC Q13936; Q08289-1: CACNB2; NbExp=4; IntAct=EBI-1038838, EBI-15707999; CC Q13936; P54284: CACNB3; NbExp=8; IntAct=EBI-1038838, EBI-1184651; CC Q13936; P62158: CALM3; NbExp=21; IntAct=EBI-1038838, EBI-397435; CC Q13936; P51114: FXR1; NbExp=2; IntAct=EBI-1038838, EBI-713291; CC Q13936; P22626: HNRNPA2B1; NbExp=2; IntAct=EBI-1038838, EBI-299649; CC Q13936; Q9HCM3: KIAA1549; NbExp=2; IntAct=EBI-1038838, EBI-311350; CC Q13936; Q06413: MEF2C; NbExp=4; IntAct=EBI-1038838, EBI-2684075; CC Q13936; Q96DH6: MSI2; NbExp=2; IntAct=EBI-1038838, EBI-2462339; CC Q13936; P42857: NSG1; NbExp=4; IntAct=EBI-1038838, EBI-6380741; CC Q13936; Q9Y5H9: PCDHA2; NbExp=2; IntAct=EBI-1038838, EBI-1754151; CC Q13936; Q9Y5E4: PCDHB5; NbExp=4; IntAct=EBI-1038838, EBI-1045222; CC Q13936; Q07343: PDE4B; NbExp=2; IntAct=EBI-1038838, EBI-1105102; CC Q13936; Q9NRD5: PICK1; NbExp=4; IntAct=EBI-1038838, EBI-79165; CC Q13936; Q9UKM9: RALY; NbExp=2; IntAct=EBI-1038838, EBI-714796; CC Q13936; Q9C0C4: SEMA4C; NbExp=3; IntAct=EBI-1038838, EBI-10303490; CC Q13936; O75533: SF3B1; NbExp=2; IntAct=EBI-1038838, EBI-876542; CC Q13936; P62161: Calm3; Xeno; NbExp=2; IntAct=EBI-1038838, EBI-397530; CC Q13936-20; Q9NZU7-2: CABP1; NbExp=2; IntAct=EBI-15896749, EBI-15896740; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11741969, CC ECO:0000269|PubMed:12176756, ECO:0000269|PubMed:12181424, CC ECO:0000269|PubMed:15454078, ECO:0000269|PubMed:15863612, CC ECO:0000269|PubMed:16299511, ECO:0000269|PubMed:17071743, CC ECO:0000269|PubMed:17224476, ECO:0000269|PubMed:20953164, CC ECO:0000269|PubMed:24728418, ECO:0000269|PubMed:26253506, CC ECO:0000269|PubMed:27218670, ECO:0000269|PubMed:29078335, CC ECO:0000269|PubMed:29742403, ECO:0000269|PubMed:7737988, CC ECO:0000269|PubMed:8099908, ECO:0000269|PubMed:8392192, CC ECO:0000269|PubMed:9013606, ECO:0000269|PubMed:9087614, CC ECO:0000269|PubMed:9607315}; Multi-pass membrane protein {ECO:0000305}. CC Cell membrane, sarcolemma {ECO:0000250|UniProtKB:P15381}; Multi-pass CC membrane protein {ECO:0000305}. Perikaryon CC {ECO:0000250|UniProtKB:P22002}. Postsynaptic density membrane CC {ECO:0000250|UniProtKB:P22002}. Cell projection, dendrite CC {ECO:0000250|UniProtKB:P22002}. Cell membrane, sarcolemma, T-tubule CC {ECO:0000250|UniProtKB:Q01815}. Note=Colocalizes with ryanodine CC receptors in distinct clusters at the junctional membrane, where the CC sarcolemma and the sarcoplasmic reticulum are in close contact. The CC interaction between RRAD and CACNB2 promotes the expression of CACNA1C CC at the cell membrane. {ECO:0000250|UniProtKB:P15381}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=37; CC Comment=Additional isoforms seem to exist. Exons 8A, 21, 22, 31, 32, CC 33, 40B, 43A, 41A and 45 are alternatively spliced in a variety of CC combinations. Experimental confirmation may be lacking for some CC isoforms.; CC Name=1; Synonyms=HFCC, Fibroblast; CC IsoId=Q13936-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13936-2; Sequence=VSP_000894; CC Name=3; CC IsoId=Q13936-3; Sequence=VSP_000886; CC Name=4; CC IsoId=Q13936-4; Sequence=VSP_000887; CC Name=5; CC IsoId=Q13936-5; Sequence=VSP_000888; CC Name=6; CC IsoId=Q13936-6; Sequence=VSP_000889; CC Name=7; CC IsoId=Q13936-7; Sequence=VSP_000890; CC Name=8; CC IsoId=Q13936-8; Sequence=VSP_000891; CC Name=9; CC IsoId=Q13936-9; Sequence=VSP_000892; CC Name=10; CC IsoId=Q13936-10; Sequence=VSP_000893; CC Name=11; Synonyms=Alpha-1C.90; CC IsoId=Q13936-11; Sequence=VSP_000895; CC Name=12; Synonyms=Alpha-1C.70; CC IsoId=Q13936-12; Sequence=VSP_000888, VSP_000889, VSP_000895; CC Name=13; Synonyms=Alpha-1C.127; CC IsoId=Q13936-13; Sequence=VSP_000888, VSP_000890, VSP_000893, CC VSP_000895; CC Name=14; Synonyms=Alpha-1C.126; CC IsoId=Q13936-14; Sequence=VSP_000888, VSP_000889, VSP_022504, CC VSP_000893, VSP_000895; CC Name=15; Synonyms=Alpha-1C.125; CC IsoId=Q13936-15; Sequence=VSP_000888, VSP_000889, VSP_022503, CC VSP_000893, VSP_000895; CC Name=16; CC IsoId=Q13936-16; Sequence=VSP_000885, VSP_000886, VSP_000888, CC VSP_000890; CC Name=17; CC IsoId=Q13936-17; Sequence=VSP_000885, VSP_000886, VSP_000888, CC VSP_000890, VSP_000895; CC Name=18; Synonyms=HHT-1; CC IsoId=Q13936-18; Sequence=VSP_000885, VSP_000886, VSP_000888, CC VSP_000890, VSP_000894; CC Name=19; Synonyms=Alpha-1C.76; CC IsoId=Q13936-19; Sequence=VSP_000887, VSP_000889, VSP_000891, CC VSP_000895; CC Name=20; Synonyms=Alpha-1C.77; CC IsoId=Q13936-20; Sequence=VSP_000887, VSP_000889, VSP_000895; CC Name=21; Synonyms=Alpha-1C.69; CC IsoId=Q13936-21; Sequence=VSP_000887, VSP_000890, VSP_000895; CC Name=22; Synonyms=Alpha-1C.78; CC IsoId=Q13936-22; Sequence=VSP_000888, VSP_000890, VSP_000895; CC Name=23; Synonyms=Alpha-1C.105; CC IsoId=Q13936-23; Sequence=VSP_000886, VSP_000887, VSP_000889, CC VSP_000895; CC Name=24; Synonyms=Alpha-1C.71; CC IsoId=Q13936-24; Sequence=VSP_000888, VSP_000889, VSP_000893, CC VSP_000895; CC Name=25; Synonyms=Alpha-1C.73; CC IsoId=Q13936-25; Sequence=VSP_000888, VSP_000889, VSP_000891, CC VSP_000893, VSP_000895; CC Name=26; Synonyms=Alpha-1C.86; CC IsoId=Q13936-26; Sequence=VSP_000887, VSP_000889, VSP_000892, CC VSP_000895; CC Name=27; Synonyms=Alpha-1C.72; CC IsoId=Q13936-27; Sequence=VSP_000887, VSP_000889, VSP_000893, CC VSP_000895; CC Name=28; CC IsoId=Q13936-28; Sequence=VSP_000885, VSP_000886, VSP_000888, CC VSP_000889, VSP_000891, VSP_000894; CC Name=29; Synonyms=Alpha-1C.74; CC IsoId=Q13936-29; Sequence=VSP_000887, VSP_000889, VSP_000891, CC VSP_000893, VSP_000895; CC Name=30; Synonyms=Alpha-1C.87; CC IsoId=Q13936-30; Sequence=VSP_000889, VSP_000895; CC Name=31; Synonyms=Alpha-1C.88; CC IsoId=Q13936-31; Sequence=VSP_000888, VSP_000895; CC Name=32; Synonyms=Alpha-1C.89; CC IsoId=Q13936-32; Sequence=VSP_000887, VSP_000891, VSP_000895; CC Name=33; Synonyms=Alpha-1C.85; CC IsoId=Q13936-33; Sequence=VSP_000887, VSP_000889; CC Name=34; Synonyms=Alpha-1C, long-NT; CC IsoId=Q13936-34; Sequence=VSP_035146; CC Name=35; CC IsoId=Q13936-35; Sequence=VSP_035877, VSP_000888, VSP_000890, CC VSP_000895; CC Name=36; CC IsoId=Q13936-36; Sequence=VSP_000886, VSP_000888, VSP_000890; CC Name=37; CC IsoId=Q13936-37; Sequence=VSP_000886, VSP_000888, VSP_000890, CC VSP_000895; CC -!- TISSUE SPECIFICITY: Detected throughout the brain, including CC hippocampus, cerebellum and amygdala, throughout the heart and vascular CC system, including ductus arteriosus, in urinary bladder, and in retina CC and sclera in the eye (PubMed:15454078). Expressed in brain, heart, CC jejunum, ovary, pancreatic beta-cells and vascular smooth muscle. CC Overall expression is reduced in atherosclerotic vascular smooth CC muscle. {ECO:0000269|PubMed:12176756, ECO:0000269|PubMed:15454078, CC ECO:0000269|PubMed:17071743, ECO:0000269|PubMed:8392192}. CC -!- DOMAIN: Each of the four internal repeats contains five hydrophobic CC transmembrane segments (S1, S2, S3, S5, S6) and one positively charged CC transmembrane segment (S4). S4 segments probably represent the voltage- CC sensor and are characterized by a series of positively charged amino CC acids at every third position. {ECO:0000305}. CC -!- DOMAIN: Binding of intracellular calcium through the EF-hand motif CC inhibits the opening of the channel. {ECO:0000250|UniProtKB:P15381}. CC -!- PTM: Phosphorylation by PKA at Ser-1981 activates the channel. Elevated CC levels of blood glucose lead to increased phosphorylation by PKA. CC {ECO:0000269|PubMed:28119464}. CC -!- DISEASE: Timothy syndrome (TS) [MIM:601005]: Disorder characterized by CC multiorgan dysfunction including lethal arrhythmias, webbing of fingers CC and toes, congenital heart disease, immune deficiency, intermittent CC hypoglycemia, cognitive abnormalities and autism. CC {ECO:0000269|PubMed:15454078, ECO:0000269|PubMed:15863612, CC ECO:0000269|PubMed:25260352, ECO:0000269|PubMed:26253506, CC ECO:0000269|PubMed:30023270, ECO:0000269|PubMed:30172029, CC ECO:0000269|PubMed:31430211, ECO:0000269|PubMed:8099908}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Brugada syndrome 3 (BRGDA3) [MIM:611875]: A heart disease CC characterized by the association of Brugada syndrome with shortened QT CC intervals. Brugada syndrome is a tachyarrhythmia characterized by right CC bundle branch block and ST segment elevation on an electrocardiogram CC (ECG). It can cause the ventricles to beat so fast that the blood is CC prevented from circulating efficiently in the body. When this situation CC occurs, the individual will faint and may die in a few minutes if the CC heart is not reset. {ECO:0000269|PubMed:17224476, CC ECO:0000269|PubMed:20817017}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Long QT syndrome 8 (LQT8) [MIM:618447]: A form of long QT CC syndrome, a heart disorder characterized by a prolonged QT interval on CC the ECG and polymorphic ventricular arrhythmias. They cause syncope and CC sudden death in response to exercise or emotional stress, and can CC present with a sentinel event of sudden cardiac death in infancy. LQT8 CC transmission pattern is consistent with autosomal dominant inheritance CC with incomplete penetrance. {ECO:0000269|PubMed:23677916, CC ECO:0000269|PubMed:24728418, ECO:0000269|PubMed:25633834, CC ECO:0000269|PubMed:30345660}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Neurodevelopmental disorder with hypotonia, language delay, CC and skeletal defects with or without seizures (NEDHLSS) [MIM:620029]: CC An autosomal dominant disorder characterized by global developmental CC delay apparent from infancy, intellectual disability, poor or absent CC speech, behavioral abnormalities, and hypotonia with delayed walking or CC inability to walk. Additional features include epilepsy, mild skeletal CC defects, and non-specific dysmorphic features. CC {ECO:0000269|PubMed:30513141, ECO:0000269|PubMed:34163037}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: [Isoform 3]: Contains exon 8a. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Lacks exon 21. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Lacks exon 22. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Lacks exon 31. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Lacks exon 32. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 8]: Lacks exon 33. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Contains exon 40B and 43A. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 10]: Contains exon 41A. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 11]: Lacks exon 45. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 20]: Predominant isoform in atherosclerotic CC vascular smooth muscle cells. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 26]: Not inhibited by calcium. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 34]: Enhanced by PKC activator. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit CC (TC 1.A.1.11) family. CACNA1C subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA02500.2; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M92269; AAA17030.1; -; Genomic_DNA. DR EMBL; M92270; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M92271; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M92272; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M92273; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M92274; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M92275; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L04568; AAA02500.2; ALT_FRAME; Genomic_DNA. DR EMBL; L04569; AAA02501.1; -; mRNA. DR EMBL; L29529; AAA51899.1; -; mRNA. DR EMBL; Z26256; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26257; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26258; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26259; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26260; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26261; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26262; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26263; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26264; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26265; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26266; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26267; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26268; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26269; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26271; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26272; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26273; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26274; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26275; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26276; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26277; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26278; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26279; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26280; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26281; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26282; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26283; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26284; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26286; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26287; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26288; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z26294; CAA81218.1; -; mRNA. DR EMBL; Z26295; CAA81219.1; -; mRNA. DR EMBL; Z26308; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z34809; CAA84340.1; -; mRNA. DR EMBL; Z34810; CAA84341.1; -; mRNA. DR EMBL; Z34811; CAA84342.1; -; mRNA. DR EMBL; Z34812; CAA84343.1; -; mRNA. DR EMBL; Z34813; CAA84344.1; -; mRNA. DR EMBL; Z34814; CAA84345.1; -; mRNA. DR EMBL; Z34815; CAA84346.1; -; mRNA. DR EMBL; Z34816; CAA84347.1; -; mRNA. DR EMBL; Z34817; CAA84348.1; -; mRNA. DR EMBL; Z34818; CAA84349.1; -; mRNA. DR EMBL; Z34819; CAA84350.1; -; mRNA. DR EMBL; Z34820; CAA84351.1; -; mRNA. DR EMBL; Z34821; CAA84352.1; -; mRNA. DR EMBL; Z34822; CAA84353.1; -; mRNA. DR EMBL; L29530; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L29531; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L29532; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L29533; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L29534; AAA51900.1; -; mRNA. DR EMBL; L29535; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L29536; AAA51901.1; -; mRNA. DR EMBL; L29537; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L29538; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L29539; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z74996; CAA99284.1; -; mRNA. DR EMBL; AJ224873; CAA12174.1; -; mRNA. DR EMBL; AF465484; AAM70049.1; -; mRNA. DR EMBL; AY830711; AAX37354.1; -; mRNA. DR EMBL; AY830712; AAX37355.1; -; mRNA. DR EMBL; AY830713; AAX37356.1; -; mRNA. DR EMBL; AC005293; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005342; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005344; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005414; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005866; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006051; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC007618; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC146846; AAI46847.1; -; mRNA. DR EMBL; AY604867; AAT02226.1; -; mRNA. DR EMBL; M57971; AAA62832.1; -; mRNA. DR EMBL; M57972; AAB59461.1; -; mRNA. DR EMBL; M61130; AAA58409.1; -; Genomic_DNA. DR EMBL; M91370; AAA74590.1; -; Genomic_DNA. DR CCDS; CCDS44787.1; -. [Q13936-23] DR CCDS; CCDS44788.1; -. [Q13936-11] DR CCDS; CCDS44789.1; -. [Q13936-30] DR CCDS; CCDS44790.1; -. [Q13936-31] DR CCDS; CCDS44791.1; -. [Q13936-22] DR CCDS; CCDS44792.1; -. [Q13936-14] DR CCDS; CCDS44793.1; -. [Q13936-24] DR CCDS; CCDS44794.1; -. [Q13936-12] DR CCDS; CCDS44795.1; -. [Q13936-25] DR CCDS; CCDS44796.1; -. [Q13936-15] DR CCDS; CCDS44797.1; -. [Q13936-32] DR CCDS; CCDS44798.1; -. [Q13936-21] DR CCDS; CCDS44799.1; -. [Q13936-27] DR CCDS; CCDS44800.1; -. [Q13936-20] DR CCDS; CCDS44801.1; -. [Q13936-29] DR CCDS; CCDS53733.1; -. [Q13936-36] DR CCDS; CCDS53734.1; -. [Q13936-37] DR CCDS; CCDS53735.1; -. [Q13936-13] DR CCDS; CCDS53736.1; -. [Q13936-33] DR CCDS; CCDS91636.1; -. [Q13936-19] DR CCDS; CCDS91637.1; -. [Q13936-35] DR PIR; A23660; A23660. DR PIR; A44363; A44363. DR PIR; A45290; A45290. DR PIR; B23660; B23660. DR PIR; C23660; C23660. DR PIR; I54168; I54168. DR RefSeq; NP_000710.5; NM_000719.7. [Q13936-12] DR RefSeq; NP_001123299.1; NM_001129827.2. [Q13936-11] DR RefSeq; NP_001123301.1; NM_001129829.2. [Q13936-14] DR RefSeq; NP_001123302.2; NM_001129830.3. DR RefSeq; NP_001123303.1; NM_001129831.2. [Q13936-31] DR RefSeq; NP_001123304.1; NM_001129832.2. [Q13936-30] DR RefSeq; NP_001123305.1; NM_001129833.2. [Q13936-13] DR RefSeq; NP_001123306.1; NM_001129834.2. [Q13936-24] DR RefSeq; NP_001123307.1; NM_001129835.2. [Q13936-27] DR RefSeq; NP_001123308.1; NM_001129836.2. [Q13936-32] DR RefSeq; NP_001123309.1; NM_001129837.2. [Q13936-25] DR RefSeq; NP_001123310.1; NM_001129838.2. [Q13936-29] DR RefSeq; NP_001123311.1; NM_001129839.2. [Q13936-15] DR RefSeq; NP_001123312.1; NM_001129840.2. [Q13936-23] DR RefSeq; NP_001123313.1; NM_001129841.2. [Q13936-21] DR RefSeq; NP_001123314.1; NM_001129842.2. [Q13936-22] DR RefSeq; NP_001123315.1; NM_001129843.2. [Q13936-20] DR RefSeq; NP_001123316.1; NM_001129844.2. [Q13936-35] DR RefSeq; NP_001123318.1; NM_001129846.2. [Q13936-19] DR RefSeq; NP_001161095.1; NM_001167623.2. [Q13936-37] DR RefSeq; NP_001161096.2; NM_001167624.3. DR RefSeq; NP_001161097.1; NM_001167625.2. DR RefSeq; NP_955630.3; NM_199460.4. DR PDB; 1T0J; X-ray; 2.00 A; C=428-445. DR PDB; 2BE6; X-ray; 2.00 A; D/E/F=1659-1692. DR PDB; 2F3Y; X-ray; 1.45 A; B=1665-1685. DR PDB; 2F3Z; X-ray; 1.60 A; B=1665-1685. DR PDB; 2LQC; NMR; -; B=47-68. DR PDB; 3G43; X-ray; 2.10 A; E/F=1609-1682. DR PDB; 3OXQ; X-ray; 2.55 A; E/F=1609-1685. DR PDB; 5V2P; X-ray; 2.00 A; B=427-445. DR PDB; 5V2Q; X-ray; 1.70 A; B=427-445. DR PDB; 6C0A; NMR; -; B=1664-1686. DR PDB; 6DAD; X-ray; 1.65 A; C/D=1659-1692. DR PDB; 6DAE; X-ray; 2.00 A; C/D=1659-1692. DR PDB; 6DAF; X-ray; 2.40 A; C/D=1659-1692. DR PDB; 6U39; X-ray; 2.40 A; B/D/F/H/J/L/N/P/R/T=1659-1692. DR PDB; 6U3A; X-ray; 1.65 A; C/D=1659-1692. DR PDB; 6U3B; X-ray; 1.70 A; B=1659-1692. DR PDB; 6U3D; X-ray; 1.75 A; C/D=1659-1692. DR PDB; 7L8V; NMR; -; C=1662-1682. DR PDB; 8EOG; EM; 3.30 A; K=112-1658. DR PDB; 8EOI; EM; 3.40 A; K=109-1658. DR PDB; 8FD7; EM; 3.10 A; K=1-1696. DR PDB; 8FHS; EM; 3.30 A; A=1-2221. DR PDB; 8HLP; EM; 3.50 A; A=1-2221. DR PDB; 8HMA; EM; 3.40 A; E=1-2221. DR PDB; 8HMB; EM; 3.30 A; D=1-2221. DR PDB; 8UKO; X-ray; 2.89 A; C=1968-1984. DR PDB; 8UKP; X-ray; 2.85 A; C=1968-1984. DR PDB; 8WE6; EM; 2.90 A; A=1-2221. DR PDB; 8WE7; EM; 3.20 A; A=1-2221. DR PDB; 8WE8; EM; 2.90 A; A=1-2221. DR PDB; 8WE9; EM; 3.00 A; A=1-2221. DR PDB; 8WEA; EM; 3.20 A; A=1-2221. DR PDB; 9ZZ4; NMR; -; B=1664-1686. DR AlphaFoldDB; Q13936; -. DR BMRB; Q13936; -. DR EMDB; EMD-28376; -. DR EMDB; EMD-29004; -. DR EMDB; EMD-29102; -. DR EMDB; EMD-37472; -. DR EMDB; EMD-37473; -. DR EMDB; EMD-37474; -. DR EMDB; EMD-37475; -. DR EMDB; EMD-37476; -. DR MDposit; Q13936; -. DR SMR; Q13936; -. DR BioGRID; 107229; 45. DR ComplexPortal; CPX-3195; Cav1.2 voltage-gated calcium channel complex, CACNA2D1-CACNB2 variant. DR ComplexPortal; CPX-8861; Cav1.2 voltage-gated calcium channel complex, CACNA2D1-CACNB3 variant. DR ComplexPortal; CPX-8862; Cav1.2 voltage-gated calcium channel complex, CACNA2D1-CACNB1 variant. DR ComplexPortal; CPX-8863; Cav1.2 voltage-gated calcium channel complex, CACNA2D1-CACNB4 variant. DR ComplexPortal; CPX-8864; Cav1.2 voltage-gated calcium channel complex, CACNA2D2-CACNB2 variant. DR ComplexPortal; CPX-8865; Cav1.2 voltage-gated calcium channel complex, CACNA2D2-CACNB1 variant. DR ComplexPortal; CPX-8866; Cav1.2 voltage-gated calcium channel complex, CACNA2D2-CACNB3 variant. DR ComplexPortal; CPX-8867; Cav1.2 voltage-gated calcium channel complex, CACNA2D2-CACNB4 variant. DR ComplexPortal; CPX-8868; Cav1.2 voltage-gated calcium channel complex, CACNA2D3-CACNB1 variant. DR ComplexPortal; CPX-8869; Cav1.2 voltage-gated calcium channel complex, CACNA2D3-CACNB2 variant. DR ComplexPortal; CPX-8870; Cav1.2 voltage-gated calcium channel complex, CACNA2D3-CACNB3 variant. DR ComplexPortal; CPX-8871; Cav1.2 voltage-gated calcium channel complex, CACNA2D3-CACNB4 variant. DR ComplexPortal; CPX-8872; Cav1.2 voltage-gated calcium channel complex, CACNA2D4-CACNB1 variant. DR ComplexPortal; CPX-8873; Cav1.2 voltage-gated calcium channel complex, CACNA2D4-CACNB2 variant. DR ComplexPortal; CPX-8875; Cav1.2 voltage-gated calcium channel complex, CACNA2D4-CACNB3 variant. DR ComplexPortal; CPX-8876; Cav1.2 voltage-gated calcium channel complex, CACNA2D4-CACNB4 variant. DR CORUM; Q13936; -. DR DIP; DIP-29589N; -. DR FunCoup; Q13936; 1542. DR IntAct; Q13936; 647. DR NDEx; IQUERY-CP-CACNA1C; 10 NDEx IQuery Curated Pathways. DR STRING; 9606.ENSP00000266376; -. DR BindingDB; Q13936; -. DR ChEMBL; CHEMBL1940; -. DR DrugBank; DB01118; Amiodarone. DR DrugBank; DB00381; Amlodipine. DR DrugBank; DB09229; Aranidipine. DR DrugBank; DB09227; Barnidipine. DR DrugBank; DB09231; Benidipine. DR DrugBank; DB13746; Bioallethrin. DR DrugBank; DB11148; Butamben. DR DrugBank; DB01373; Calcium. DR DrugBank; DB11093; Calcium citrate. DR DrugBank; DB11348; Calcium Phosphate. DR DrugBank; DB14481; Calcium phosphate dihydrate. DR DrugBank; DB09232; Cilnidipine. DR DrugBank; DB00568; Cinnarizine. DR DrugBank; DB04920; Clevidipine. DR DrugBank; DB00343; Diltiazem. DR DrugBank; DB04855; Dronedarone. DR DrugBank; DB06751; Drotaverine. DR DrugBank; DB09235; Efonidipine. DR DrugBank; DB00228; Enflurane. DR DrugBank; DB00153; Ergocalciferol. DR DrugBank; DB00898; Ethanol. DR DrugBank; DB12605; Etripamil. DR DrugBank; DB01023; Felodipine. DR DrugBank; DB13961; Fish oil. DR DrugBank; DB00308; Ibutilide. DR DrugBank; DB11633; Isavuconazole. DR DrugBank; DB00270; Isradipine. DR DrugBank; DB09236; Lacidipine. DR DrugBank; DB09237; Levamlodipine. DR DrugBank; DB00825; Levomenthol. DR DrugBank; DB00653; Magnesium sulfate. DR DrugBank; DB09238; Manidipine. DR DrugBank; DB01388; Mibefradil. DR DrugBank; DB01110; Miconazole. DR DrugBank; DB00622; Nicardipine. DR DrugBank; DB01115; Nifedipine. DR DrugBank; DB09239; Niguldipine. DR DrugBank; DB06712; Nilvadipine. DR DrugBank; DB00393; Nimodipine. DR DrugBank; DB00401; Nisoldipine. DR DrugBank; DB01054; Nitrendipine. DR DrugBank; DB00252; Phenytoin. DR DrugBank; DB12278; Propiverine. DR DrugBank; DB00243; Ranolazine. DR DrugBank; DB00421; Spironolactone. DR DrugBank; DB00273; Topiramate. DR DrugBank; DB09089; Trimebutine. DR DrugBank; DB00661; Verapamil. DR DrugCentral; Q13936; -. DR GuidetoPHARMACOLOGY; 529; -. DR TCDB; 1.A.1.11.4; the voltage-gated ion channel (vic) superfamily. DR GlyCosmos; Q13936; 5 sites, 1 glycan. DR GlyGen; Q13936; 7 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q13936; -. DR PhosphoSitePlus; Q13936; -. DR BioMuta; CACNA1C; -. DR DMDM; 308153651; -. DR jPOST; Q13936; -. DR MassIVE; Q13936; -. DR PaxDb; 9606-ENSP00000266376; -. DR PeptideAtlas; Q13936; -. DR ProteomicsDB; 19675; -. DR ProteomicsDB; 59725; -. [Q13936-1] DR ProteomicsDB; 59726; -. [Q13936-10] DR ProteomicsDB; 59727; -. [Q13936-11] DR ProteomicsDB; 59728; -. [Q13936-12] DR ProteomicsDB; 59729; -. [Q13936-13] DR ProteomicsDB; 59730; -. [Q13936-14] DR ProteomicsDB; 59731; -. [Q13936-15] DR ProteomicsDB; 59732; -. [Q13936-16] DR ProteomicsDB; 59733; -. [Q13936-17] DR ProteomicsDB; 59734; -. [Q13936-18] DR ProteomicsDB; 59735; -. [Q13936-19] DR ProteomicsDB; 59736; -. [Q13936-2] DR ProteomicsDB; 59737; -. [Q13936-20] DR ProteomicsDB; 59738; -. [Q13936-21] DR ProteomicsDB; 59739; -. [Q13936-22] DR ProteomicsDB; 59740; -. [Q13936-23] DR ProteomicsDB; 59741; -. [Q13936-24] DR ProteomicsDB; 59742; -. [Q13936-25] DR ProteomicsDB; 59743; -. [Q13936-26] DR ProteomicsDB; 59744; -. [Q13936-27] DR ProteomicsDB; 59745; -. [Q13936-28] DR ProteomicsDB; 59746; -. [Q13936-29] DR ProteomicsDB; 59747; -. [Q13936-3] DR ProteomicsDB; 59748; -. [Q13936-30] DR ProteomicsDB; 59749; -. [Q13936-31] DR ProteomicsDB; 59750; -. [Q13936-32] DR ProteomicsDB; 59751; -. [Q13936-33] DR ProteomicsDB; 59752; -. [Q13936-34] DR ProteomicsDB; 59753; -. [Q13936-35] DR ProteomicsDB; 59754; -. [Q13936-4] DR ProteomicsDB; 59755; -. [Q13936-5] DR ProteomicsDB; 59756; -. [Q13936-6] DR ProteomicsDB; 59757; -. [Q13936-7] DR ProteomicsDB; 59758; -. [Q13936-8] DR ProteomicsDB; 59759; -. [Q13936-9] DR ABCD; Q13936; 2 sequenced antibodies. DR Antibodypedia; 22118; 556 antibodies from 40 providers. DR DNASU; 775; -. DR Ensembl; ENST00000344100.7; ENSP00000341092.3; ENSG00000151067.23. [Q13936-14] DR Ensembl; ENST00000347598.9; ENSP00000266376.6; ENSG00000151067.23. [Q13936-11] DR Ensembl; ENST00000399591.5; ENSP00000382500.1; ENSG00000151067.23. [Q13936-29] DR Ensembl; ENST00000399595.5; ENSP00000382504.1; ENSG00000151067.23. [Q13936-25] DR Ensembl; ENST00000399597.5; ENSP00000382506.1; ENSG00000151067.23. [Q13936-22] DR Ensembl; ENST00000399601.5; ENSP00000382510.1; ENSG00000151067.23. [Q13936-20] DR Ensembl; ENST00000399603.6; ENSP00000382512.1; ENSG00000151067.23. [Q13936-37] DR Ensembl; ENST00000399606.5; ENSP00000382515.1; ENSG00000151067.23. [Q13936-30] DR Ensembl; ENST00000399621.5; ENSP00000382530.1; ENSG00000151067.23. [Q13936-24] DR Ensembl; ENST00000399629.5; ENSP00000382537.1; ENSG00000151067.23. [Q13936-32] DR Ensembl; ENST00000399637.5; ENSP00000382546.1; ENSG00000151067.23. [Q13936-27] DR Ensembl; ENST00000399638.5; ENSP00000382547.1; ENSG00000151067.23. [Q13936-31] DR Ensembl; ENST00000399641.6; ENSP00000382549.1; ENSG00000151067.23. [Q13936-23] DR Ensembl; ENST00000399644.5; ENSP00000382552.1; ENSG00000151067.23. [Q13936-21] DR Ensembl; ENST00000399649.5; ENSP00000382557.1; ENSG00000151067.23. [Q13936-15] DR Ensembl; ENST00000399655.6; ENSP00000382563.1; ENSG00000151067.23. [Q13936-12] DR Ensembl; ENST00000402845.7; ENSP00000385724.3; ENSG00000151067.23. [Q13936-13] DR Ensembl; ENST00000642583.1; ENSP00000494999.1; ENSG00000285479.3. [Q13936-29] DR Ensembl; ENST00000643038.2; ENSP00000494095.1; ENSG00000285479.3. [Q13936-11] DR Ensembl; ENST00000643138.1; ENSP00000496049.1; ENSG00000285479.3. [Q13936-22] DR Ensembl; ENST00000643701.1; ENSP00000496458.1; ENSG00000285479.3. [Q13936-15] DR Ensembl; ENST00000643858.1; ENSP00000495576.1; ENSG00000285479.3. [Q13936-14] DR Ensembl; ENST00000644048.1; ENSP00000494782.1; ENSG00000285479.3. [Q13936-31] DR Ensembl; ENST00000644235.2; ENSP00000494058.1; ENSG00000285479.3. [Q13936-12] DR Ensembl; ENST00000644369.2; ENSP00000494765.1; ENSG00000285479.3. [Q13936-23] DR Ensembl; ENST00000644660.1; ENSP00000496749.1; ENSG00000285479.3. [Q13936-20] DR Ensembl; ENST00000644691.1; ENSP00000494420.1; ENSG00000285479.3. [Q13936-30] DR Ensembl; ENST00000644891.1; ENSP00000496681.1; ENSG00000285479.3. [Q13936-32] DR Ensembl; ENST00000645584.1; ENSP00000494018.1; ENSG00000285479.3. [Q13936-24] DR Ensembl; ENST00000645965.1; ENSP00000493890.1; ENSG00000285479.3. [Q13936-27] DR Ensembl; ENST00000646257.1; ENSP00000493573.1; ENSG00000285479.3. [Q13936-21] DR Ensembl; ENST00000647062.1; ENSP00000495080.1; ENSG00000285479.3. [Q13936-13] DR Ensembl; ENST00000647327.2; ENSP00000493781.1; ENSG00000285479.3. [Q13936-37] DR Ensembl; ENST00000647521.1; ENSP00000495678.1; ENSG00000285479.3. [Q13936-25] DR Ensembl; ENST00000682686.1; ENSP00000507309.1; ENSG00000151067.23. [Q13936-19] DR Ensembl; ENST00000683482.1; ENSP00000507169.1; ENSG00000151067.23. [Q13936-35] DR Ensembl; ENST00000710479.1; ENSP00000518305.1; ENSG00000285479.3. [Q13936-35] DR Ensembl; ENST00000710487.1; ENSP00000518307.1; ENSG00000285479.3. [Q13936-19] DR GeneID; 775; -. DR KEGG; hsa:775; -. DR MANE-Select; ENST00000399655.6; ENSP00000382563.1; NM_000719.7; NP_000710.5. [Q13936-12] DR UCSC; uc001qjz.3; human. [Q13936-1] DR AGR; HGNC:1390; -. DR ClinPGx; PA83; -. DR CTD; 775; -. DR DisGeNET; 775; -. DR GeneCards; CACNA1C; -. DR GeneReviews; CACNA1C; -. DR HGNC; HGNC:1390; CACNA1C. DR HPA; ENSG00000151067; Tissue enhanced (intestine). DR MalaCards; CACNA1C; -. DR MIM; 114205; gene. DR MIM; 601005; phenotype. DR MIM; 611875; phenotype. DR MIM; 618447; phenotype. DR MIM; 620029; phenotype. DR OpenTargets; ENSG00000151067; -. DR Orphanet; 595109; Atypical Timothy syndrome. DR Orphanet; 130; Brugada syndrome. DR Orphanet; 727156; CACNA1C-related isolated congenital Long QT syndrome. DR Orphanet; 528084; Non-specific syndromic intellectual disability. DR Orphanet; 595098; Timothy syndrome type 1. DR Orphanet; 595105; Timothy syndrome type 2. DR VEuPathDB; HostDB:ENSG00000151067; -. DR eggNOG; KOG2301; Eukaryota. DR GeneTree; ENSGT00940000156127; -. DR InParanoid; Q13936; -. DR OrthoDB; 431720at2759; -. DR PAN-GO; Q13936; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q13936; -. DR PathwayCommons; Q13936; -. DR Reactome; R-HSA-400042; Adrenaline,noradrenaline inhibits insulin secretion. DR Reactome; R-HSA-419037; NCAM1 interactions. DR Reactome; R-HSA-422356; Regulation of insulin secretion. DR Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation. DR Reactome; R-HSA-5576893; Phase 2 - plateau phase. DR SignaLink; Q13936; -. DR SIGNOR; Q13936; -. DR Agora; ENSG00000151067; -. DR BioGRID-ORCS; 775; 13 hits in 1159 CRISPR screens. DR ChiTaRS; CACNA1C; human. DR EvolutionaryTrace; Q13936; -. DR GeneWiki; Cav1.2; -. DR GenomeRNAi; 775; -. DR Pharos; Q13936; Tclin. DR PRO; PR:Q13936; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q13936; protein. DR Bgee; ENSG00000151067; Expressed in apex of heart and 101 other cell types or tissues. DR ExpressionAtlas; Q13936; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell. DR GO; GO:1990454; C:L-type voltage-gated calcium channel complex; IDA:BHF-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0043204; C:perikaryon; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; IDA:UniProtKB. DR GO; GO:0098839; C:postsynaptic density membrane; ISS:UniProtKB. DR GO; GO:0005891; C:voltage-gated calcium channel complex; IDA:UniProtKB. DR GO; GO:0030018; C:Z disc; ISS:BHF-UCL. DR GO; GO:0051393; F:alpha-actinin binding; IPI:BHF-UCL. DR GO; GO:0005516; F:calmodulin binding; IPI:UniProtKB. DR GO; GO:0008331; F:high voltage-gated calcium channel activity; IDA:BHF-UCL. DR GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB. DR GO; GO:0086056; F:voltage-gated calcium channel activity involved in AV node cell action potential; IMP:BHF-UCL. DR GO; GO:0086007; F:voltage-gated calcium channel activity involved in cardiac muscle cell action potential; IMP:BHF-UCL. DR GO; GO:0098703; P:calcium ion import across plasma membrane; IBA:GO_Central. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:BHF-UCL. DR GO; GO:0061577; P:calcium ion transmembrane transport via high voltage-gated calcium channel; IDA:BHF-UCL. DR GO; GO:0060402; P:calcium ion transport into cytosol; ISS:UniProtKB. DR GO; GO:0043010; P:camera-type eye development; IMP:BHF-UCL. DR GO; GO:0061337; P:cardiac conduction; IMP:UniProtKB. DR GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; IMP:BHF-UCL. DR GO; GO:0086064; P:cell communication by electrical coupling involved in cardiac conduction; TAS:BHF-UCL. DR GO; GO:0035115; P:embryonic forelimb morphogenesis; IMP:BHF-UCL. DR GO; GO:0007507; P:heart development; IMP:BHF-UCL. DR GO; GO:0002520; P:immune system development; IMP:BHF-UCL. DR GO; GO:0098912; P:membrane depolarization during atrial cardiac muscle cell action potential; IMP:BHF-UCL. DR GO; GO:0086045; P:membrane depolarization during AV node cell action potential; IMP:BHF-UCL. DR GO; GO:0086012; P:membrane depolarization during cardiac muscle cell action potential; IMP:BHF-UCL. DR GO; GO:0045762; P:positive regulation of adenylate cyclase activity; ISS:UniProtKB. DR GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB. DR GO; GO:0045933; P:positive regulation of muscle contraction; NAS:ComplexPortal. DR GO; GO:0010881; P:regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion; ISS:UniProtKB. DR GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IMP:BHF-UCL. DR GO; GO:0098911; P:regulation of ventricular cardiac muscle cell action potential; IMP:BHF-UCL. DR FunFam; 1.10.287.70:FF:000007; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.10.287.70:FF:000008; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.10.287.70:FF:000009; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.10.287.70:FF:000021; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.20.120.350:FF:000001; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.20.120.350:FF:000010; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.20.120.350:FF:000037; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.20.120.350:FF:000051; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.20.120.350:FF:000060; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.20.120.350:FF:000069; Voltage-dependent L-type calcium channel subunit alpha; 1. DR FunFam; 1.10.238.10:FF:000063; Voltage-dependent N-type calcium channel subunit alpha; 1. DR Gene3D; 1.10.287.70; -; 4. DR Gene3D; 6.10.250.2180; -; 1. DR Gene3D; 6.10.250.2500; -; 1. DR Gene3D; 1.20.120.350; Voltage-gated potassium channels. Chain C; 6. DR InterPro; IPR031688; CAC1F_C. DR InterPro; IPR031649; GPHH_dom. DR InterPro; IPR005821; Ion_trans_dom. DR InterPro; IPR014873; VDCC_a1su_IQ. DR InterPro; IPR050599; VDCC_alpha-1_subunit. DR InterPro; IPR005451; VDCC_L_a1csu. DR InterPro; IPR005446; VDCC_L_a1su. DR InterPro; IPR002077; VDCCAlpha1. DR InterPro; IPR027359; Volt_channel_dom_sf. DR PANTHER; PTHR45628; VOLTAGE-DEPENDENT CALCIUM CHANNEL TYPE A SUBUNIT ALPHA-1; 1. DR PANTHER; PTHR45628:SF10; VOLTAGE-DEPENDENT L-TYPE CALCIUM CHANNEL SUBUNIT ALPHA-1C; 1. DR Pfam; PF08763; Ca_chan_IQ; 1. DR Pfam; PF16885; CAC1F_C; 1. DR Pfam; PF16905; GPHH; 1. DR Pfam; PF00520; Ion_trans; 5. DR PRINTS; PR00167; CACHANNEL. DR PRINTS; PR01630; LVDCCALPHA1. DR PRINTS; PR01635; LVDCCALPHA1C. DR SMART; SM01062; Ca_chan_IQ; 1. DR SUPFAM; SSF81324; Voltage-gated potassium channels; 4. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Autism; Autism spectrum disorder; KW Brugada syndrome; Calcium; Calcium channel; Calcium transport; KW Calmodulin-binding; Cell membrane; Cell projection; Disease variant; KW Disulfide bond; Epilepsy; Glycoprotein; Host-virus interaction; KW Intellectual disability; Ion channel; Ion transport; Long QT syndrome; KW Membrane; Metal-binding; Phosphoprotein; Postsynaptic cell membrane; KW Proteomics identification; Reference proteome; Repeat; Synapse; KW Transmembrane; Transmembrane helix; Transport; Voltage-gated channel. FT CHAIN 1..2221 FT /note="Voltage-dependent L-type calcium channel subunit FT alpha-1C" FT /id="PRO_0000053928" FT TOPO_DOM 1..124 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 125..143 FT /note="Helical; Name=S1 of repeat I" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 144..158 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 159..179 FT /note="Helical; Name=S2 of repeat I" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 180..188 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 189..209 FT /note="Helical; Name=S3 of repeat I" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 210..232 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 233..251 FT /note="Helical; Name=S4 of repeat I" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 252..268 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 269..290 FT /note="Helical; Name=S5 of repeat I" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 291..350 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 351..372 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 373..380 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 381..401 FT /note="Helical; Name=S6 of repeat I" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 402..524 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 525..543 FT /note="Helical; Name=S1 of repeat II" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 544..554 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 555..575 FT /note="Helical; Name=S2 of repeat II" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 576..586 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 587..606 FT /note="Helical; Name=S3 of repeat II" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 607..615 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 616..634 FT /note="Helical; Name=S4 of repeat II" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 635..653 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 654..673 FT /note="Helical; Name=S5 of repeat II" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 674..693 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 694..715 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 716..725 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 726..745 FT /note="Helical; Name=S6 of repeat II" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 746..900 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 901..919 FT /note="Helical; Name=S1 of repeat III" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 920..931 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 932..952 FT /note="Helical; Name=S2 of repeat III" FT /evidence="ECO:0000255" FT TOPO_DOM 953..987 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 988..1006 FT /note="Helical; Name=S3 of repeat III" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1007..1013 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1014..1032 FT /note="Helical; Name=S4 of repeat III" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1033..1051 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1052..1071 FT /note="Helical; Name=S5 of repeat III" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1072..1121 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1122..1142 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1143..1159 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1160..1181 FT /note="Helical; Name=S6 of repeat III" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1182..1239 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1240..1261 FT /note="Helical; Name=S1 of repeat IV" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1262..1269 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1270..1291 FT /note="Helical; Name=S2 of repeat IV" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1292..1301 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1302..1321 FT /note="Helical; Name=S3 of repeat IV" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1322..1372 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1373..1391 FT /note="Helical; Name=S4 of repeat IV" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1392..1409 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1410..1430 FT /note="Helical; Name=S5 of repeat IV" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1431..1452 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1453..1471 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1472..1499 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1500..1524 FT /note="Helical; Name=S6 of repeat IV" FT /evidence="ECO:0000250|UniProtKB:P07293" FT TOPO_DOM 1525..2221 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT REPEAT 111..408 FT /note="I" FT REPEAT 510..756 FT /note="II" FT REPEAT 887..1189 FT /note="III" FT REPEAT 1226..1527 FT /note="IV" FT REGION 1..20 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 47..68 FT /note="Calmodulin-binding" FT /evidence="ECO:0000269|PubMed:22518098" FT REGION 73..98 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 428..445 FT /note="AID/alpha-interaction domain; mediates interaction FT with the beta subunit" FT /evidence="ECO:0000269|PubMed:15141227" FT REGION 449..481 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 764..861 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 829..876 FT /note="Interaction with STAC2" FT /evidence="ECO:0000269|PubMed:29078335" FT REGION 1109..1198 FT /note="Dihydropyridine binding" FT /evidence="ECO:0000250|UniProtKB:P07293" FT REGION 1478..1546 FT /note="Dihydropyridine binding" FT /evidence="ECO:0000250|UniProtKB:P07293" FT REGION 1492..1534 FT /note="Phenylalkylamine binding" FT /evidence="ECO:0000250|UniProtKB:P07293" FT REGION 1659..1686 FT /note="Important for interaction with STAC1, STAC2 and FT STAC3" FT /evidence="ECO:0000250|UniProtKB:P15381" FT REGION 1665..1685 FT /note="Calmodulin-binding IQ region" FT /evidence="ECO:0000269|PubMed:16299511, FT ECO:0000269|PubMed:16338416, ECO:0000269|PubMed:19279214, FT ECO:0000269|PubMed:20953164" FT REGION 1699..1718 FT /note="Important for localization in at the junctional FT membrane" FT /evidence="ECO:0000250|UniProtKB:P15381" FT REGION 1778..1847 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2029..2063 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2186..2221 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 361..364 FT /note="Selectivity filter of repeat I" FT /evidence="ECO:0000250|UniProtKB:P07293" FT MOTIF 704..707 FT /note="Selectivity filter of repeat II" FT /evidence="ECO:0000250|UniProtKB:P07293" FT MOTIF 1133..1136 FT /note="Selectivity filter of repeat III" FT /evidence="ECO:0000250|UniProtKB:P07293" FT MOTIF 1462..1465 FT /note="Selectivity filter of repeat IV" FT /evidence="ECO:0000250|UniProtKB:P07293" FT COMPBIAS 80..91 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 465..478 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 783..792 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 843..852 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1799..1811 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1812..1822 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 363 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000269|PubMed:37972591, FT ECO:0007744|PDB:8FHS, ECO:0007744|PDB:8WE6, FT ECO:0007744|PDB:8WE7, ECO:0007744|PDB:8WE8, FT ECO:0007744|PDB:8WE9" FT BINDING 706 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000269|PubMed:37972591, FT ECO:0007744|PDB:8FHS, ECO:0007744|PDB:8WE6, FT ECO:0007744|PDB:8WE7, ECO:0007744|PDB:8WE8, FT ECO:0007744|PDB:8WE9" FT BINDING 1135 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000269|PubMed:37972591, FT ECO:0007744|PDB:8FHS, ECO:0007744|PDB:8WE6, FT ECO:0007744|PDB:8WE7, ECO:0007744|PDB:8WE8, FT ECO:0007744|PDB:8WE9" FT SITE 363 FT /note="Calcium ion selectivity and permeability" FT /evidence="ECO:0000269|PubMed:8099908" FT SITE 1135 FT /note="Calcium ion selectivity and permeability" FT /evidence="ECO:0000269|PubMed:8099908" FT SITE 1464 FT /note="Calcium ion selectivity and permeability" FT /evidence="ECO:0000269|PubMed:8099908" FT MOD_RES 469 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q01815" FT MOD_RES 476 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q01815" FT MOD_RES 808 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q01815" FT MOD_RES 815 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q01815" FT MOD_RES 1718 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q01815" FT MOD_RES 1739 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q01815" FT MOD_RES 1981 FT /note="Phosphoserine; by PKA" FT /evidence="ECO:0000269|PubMed:28119464" FT CARBOHYD 153 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 328 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1436 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0007744|PDB:8WE6, ECO:0007744|PDB:8WE7, FT ECO:0007744|PDB:8WE8, ECO:0007744|PDB:8WE9" FT CARBOHYD 1487 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 298..326 FT /evidence="ECO:0000269|PubMed:37972591, FT ECO:0007744|PDB:8FHS, ECO:0007744|PDB:8WE6, FT ECO:0007744|PDB:8WE7, ECO:0007744|PDB:8WE8, FT ECO:0007744|PDB:8WE9, ECO:0007744|PDB:8WEA" FT DISULFID 316..332 FT /evidence="ECO:0000269|PubMed:37972591, FT ECO:0007744|PDB:8FHS, ECO:0007744|PDB:8WE6, FT ECO:0007744|PDB:8WE7, ECO:0007744|PDB:8WE8, FT ECO:0007744|PDB:8WE9, ECO:0007744|PDB:8WEA" FT DISULFID 1078..1089 FT /evidence="ECO:0000269|PubMed:37972591, FT ECO:0007744|PDB:8FHS, ECO:0007744|PDB:8WE6, FT ECO:0007744|PDB:8WE7, ECO:0007744|PDB:8WE8, FT ECO:0007744|PDB:8WE9, ECO:0007744|PDB:8WEA" FT DISULFID 1479..1495 FT /evidence="ECO:0000269|PubMed:37972591, FT ECO:0007744|PDB:8FHS, ECO:0007744|PDB:8WE6, FT ECO:0007744|PDB:8WE7, ECO:0007744|PDB:8WE8, FT ECO:0007744|PDB:8WE9, ECO:0007744|PDB:8WEA" FT VAR_SEQ 1..29 FT /note="Missing (in isoform 16, isoform 17, isoform 18 and FT isoform 28)" FT /evidence="ECO:0000303|PubMed:8392192, FT ECO:0000303|PubMed:9087614, ECO:0000303|Ref.10" FT /id="VSP_000885" FT VAR_SEQ 1..16 FT /note="MVNENTRMYIPEENHQ -> MLRAFVQPGTPAYQPLPSHLSANTEVKFKGTL FT VHEAQLNYFYISPG (in isoform 34)" FT /evidence="ECO:0000303|PubMed:11741969" FT /id="VSP_035146" FT VAR_SEQ 306..308 FT /note="Missing (in isoform 35)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035877" FT VAR_SEQ 372..391 FT /note="VNDAVGRDWPWIYFVTLIII -> MQDAMGYELPWVYFVSLVIF (in FT isoform 3, isoform 16, isoform 17, isoform 18, isoform 23, FT isoform 28, isoform 36 and isoform 37)" FT /evidence="ECO:0000303|PubMed:8392192, FT ECO:0000303|PubMed:9087614, ECO:0000303|PubMed:9607315, FT ECO:0000303|Ref.10" FT /id="VSP_000886" FT VAR_SEQ 932..951 FT /note="Missing (in isoform 4, isoform 19, isoform 20, FT isoform 21, isoform 23, isoform 26, isoform 27, isoform 29, FT isoform 32 and isoform 33)" FT /evidence="ECO:0000303|PubMed:7737988, FT ECO:0000303|PubMed:9013606, ECO:0000303|PubMed:9607315, FT ECO:0000303|Ref.10" FT /id="VSP_000887" FT VAR_SEQ 952..971 FT /note="Missing (in isoform 5, isoform 12, isoform 13, FT isoform 14, isoform 15, isoform 16, isoform 17, isoform 18, FT isoform 22, isoform 24, isoform 25, isoform 28, isoform 31, FT isoform 35, isoform 36 and isoform 37)" FT /evidence="ECO:0000303|PubMed:12176756, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17071743, FT ECO:0000303|PubMed:7737988, ECO:0000303|PubMed:8392192, FT ECO:0000303|PubMed:9087614, ECO:0000303|PubMed:9607315, FT ECO:0000303|Ref.10" FT /id="VSP_000888" FT VAR_SEQ 1297..1324 FT /note="Missing (in isoform 6, isoform 12, isoform 14, FT isoform 15, isoform 19, isoform 20, isoform 23, isoform 24, FT isoform 25, isoform 26, isoform 27, isoform 28, isoform 29, FT isoform 30 and isoform 33)" FT /evidence="ECO:0000303|PubMed:12176756, FT ECO:0000303|PubMed:17071743, ECO:0000303|PubMed:7737988, FT ECO:0000303|PubMed:8392192, ECO:0000303|PubMed:9013606, FT ECO:0000303|PubMed:9607315, ECO:0000303|Ref.10" FT /id="VSP_000889" FT VAR_SEQ 1325..1352 FT /note="Missing (in isoform 7, isoform 13, isoform 16, FT isoform 17, isoform 18, isoform 21, isoform 22, isoform 35, FT isoform 36 and isoform 37)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17071743, ECO:0000303|PubMed:8392192, FT ECO:0000303|PubMed:9087614, ECO:0000303|PubMed:9607315" FT /id="VSP_000890" FT VAR_SEQ 1351..1363 FT /note="Missing (in isoform 15)" FT /evidence="ECO:0000303|PubMed:17071743" FT /id="VSP_022503" FT VAR_SEQ 1353..1363 FT /note="Missing (in isoform 8, isoform 19, isoform 25, FT isoform 28, isoform 29 and isoform 32)" FT /evidence="ECO:0000303|PubMed:17071743, FT ECO:0000303|PubMed:7737988, ECO:0000303|PubMed:8392192, FT ECO:0000303|Ref.10" FT /id="VSP_000891" FT VAR_SEQ 1363 FT /note="M -> MGPSCSHPPLAVLTAPPVADGFQ (in isoform 14)" FT /evidence="ECO:0000303|PubMed:17071743" FT /id="VSP_022504" FT VAR_SEQ 1618..1699 FT /note="LRIKTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGDDEVTVGKFYAT FT FLIQEYFRKFKKRKEQGLVGKPSQRNALSL -> LREAELSSQVQYQAKEASLLERRRK FT SSHPKSSTKPNKLLSSGGSTGWVEDARALEGQVLARGCGWLGSLEERERGPHHPPLGF FT (in isoform 9 and isoform 26)" FT /evidence="ECO:0000303|PubMed:9013606" FT /id="VSP_000892" FT VAR_SEQ 1623 FT /note="E -> EEGPSPSEAHQGAEDPFRPA (in isoform 10, isoform FT 13, isoform 14, isoform 15, isoform 24, isoform 25, isoform FT 27 and isoform 29)" FT /evidence="ECO:0000303|PubMed:17071743, FT ECO:0000303|PubMed:9013606, ECO:0000303|Ref.10" FT /id="VSP_000893" FT VAR_SEQ 1864..1898 FT /note="Missing (in isoform 11, isoform 12, isoform 13, FT isoform 14, isoform 15, isoform 17, isoform 19, isoform 20, FT isoform 21, isoform 22, isoform 23, isoform 24, isoform 25, FT isoform 26, isoform 27, isoform 29, isoform 30, isoform 31, FT isoform 32, isoform 35 and isoform 37)" FT /evidence="ECO:0000303|PubMed:12176756, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17071743, FT ECO:0000303|PubMed:7737988, ECO:0000303|PubMed:9013606, FT ECO:0000303|PubMed:9087614, ECO:0000303|PubMed:9607315, FT ECO:0000303|Ref.10" FT /id="VSP_000895" FT VAR_SEQ 1864..1897 FT /note="ERHVPMCEDLELRRDSGSAGTQAHCLLLRKANPS -> MHCCDMLDGGTFPP FT ALGPRRAPPCLHQQLQGSLAGLREDTPCIVPGHASLCCSSRVGEWLPAGCTAPQHA FT (in isoform 2, isoform 18 and isoform 28)" FT /evidence="ECO:0000303|PubMed:8392192, ECO:0000303|Ref.10" FT /id="VSP_000894" FT VARIANT 28 FT /note="A -> T (in LQT8; uncertain significance; increased FT channel activity)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075148" FT VARIANT 37 FT /note="G -> R" FT /evidence="ECO:0000269|PubMed:20817017, FT ECO:0000269|PubMed:25633834" FT /id="VAR_075149" FT VARIANT 39 FT /note="A -> V (in BRGDA3; uncertain significance; affects FT channel activity)" FT /evidence="ECO:0000269|PubMed:17224476, FT ECO:0000269|PubMed:20817017" FT /id="VAR_044039" FT VARIANT 84 FT /note="Q -> R (in dbSNP:rs1051345)" FT /evidence="ECO:0000269|PubMed:8392192, FT ECO:0000269|PubMed:9087614, ECO:0000269|Ref.10" FT /id="VAR_045987" FT VARIANT 161..2221 FT /note="Missing (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087754" FT VARIANT 166 FT /note="F -> L (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087755" FT VARIANT 177 FT /note="K -> R (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087756" FT VARIANT 304 FT /note="I -> T" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075150" FT VARIANT 324 FT /note="R -> W (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087757" FT VARIANT 381 FT /note="P -> S (in LQT8; uncertain significance; no effect FT on channel activity)" FT /evidence="ECO:0000269|PubMed:24728418" FT /id="VAR_075151" FT VARIANT 391 FT /note="I -> L (in dbSNP:rs1051356)" FT /id="VAR_045988" FT VARIANT 402 FT /note="G -> S (in TS)" FT /evidence="ECO:0000269|PubMed:15863612" FT /id="VAR_026741" FT VARIANT 403 FT /note="V -> M (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087758" FT VARIANT 406 FT /note="G -> R (in TS; causes a nearly complete loss of FT voltage-dependent channel inactivation)" FT /evidence="ECO:0000269|PubMed:15454078" FT /id="VAR_026742" FT VARIANT 456 FT /note="M -> I (in LQT8; uncertain significance; no effect FT on channel activity)" FT /evidence="ECO:0000269|PubMed:24728418" FT /id="VAR_075152" FT VARIANT 477 FT /note="E -> K (in LQT8; uncertain significance)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075153" FT VARIANT 490 FT /note="G -> R (in BRGDA3; uncertain significance; results FT in reduced current amplitudes although voltage at peak FT current is unchanged)" FT /evidence="ECO:0000269|PubMed:17224476, FT ECO:0000269|PubMed:20817017" FT /id="VAR_044040" FT VARIANT 518 FT /note="R -> C (in TS; likely pathogenic; only with cardiac FT manifestation; decreased current density; associated with FT slower inactivation; altered localization; increase in late FT calcium current)" FT /evidence="ECO:0000269|PubMed:26253506, FT ECO:0000269|PubMed:31430211" FT /id="VAR_075154" FT VARIANT 518 FT /note="R -> H (in TS; likely pathogenic; only with cardiac FT manifestation; decreased current density; associated with FT slower inactivation)" FT /evidence="ECO:0000269|PubMed:26253506" FT /id="VAR_075155" FT VARIANT 528..2221 FT /note="Missing (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087759" FT VARIANT 582 FT /note="A -> D (in LQT8; gain-of-function effect on channel FT activity; slower inactivation)" FT /evidence="ECO:0000269|PubMed:24728418" FT /id="VAR_075156" FT VARIANT 601 FT /note="L -> R (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087760" FT VARIANT 611 FT /note="M -> T (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087761" FT VARIANT 614 FT /note="L -> P (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087762" FT VARIANT 614 FT /note="L -> R (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087763" FT VARIANT 643 FT /note="S -> F (in TS; affects voltage-gated calcium channel FT activity resulting in a marked decrease in peak currents FT and increased late currents)" FT /evidence="ECO:0000269|PubMed:30023270" FT /id="VAR_087764" FT VARIANT 657 FT /note="L -> F (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087765" FT VARIANT 743 FT /note="Missing (in NEDHLSS; uncertain significance)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087766" FT VARIANT 752 FT /note="A -> T" FT /id="VAR_001495" FT VARIANT 817 FT /note="P -> S" FT /evidence="ECO:0000269|PubMed:20817017, FT ECO:0000269|PubMed:25633834" FT /id="VAR_075157" FT VARIANT 834 FT /note="K -> E (in LQT8; uncertain significance)" FT /evidence="ECO:0000269|PubMed:23677916" FT /id="VAR_082632" FT VARIANT 850 FT /note="Missing (found in a case of sudden unexplained death FT in the young; also found in a patient with early FT repolarization syndrome; uncertain significance; results in FT reduced whole-cell calcium currents)" FT /evidence="ECO:0000269|PubMed:20817017, FT ECO:0000269|PubMed:27218670" FT /id="VAR_076414" FT VARIANT 857 FT /note="P -> L (in LQT8)" FT /evidence="ECO:0000269|PubMed:23677916" FT /id="VAR_082633" FT VARIANT 857 FT /note="P -> R (in LQT8; leads to increased calcium FT currents; increased surface membrane expression of the FT channel)" FT /evidence="ECO:0000269|PubMed:23677916" FT /id="VAR_082634" FT VARIANT 858 FT /note="R -> H (in LQT8; gain-of-function effect on channel FT activity; slower inactivation)" FT /evidence="ECO:0000269|PubMed:24728418, FT ECO:0000269|PubMed:30345660" FT /id="VAR_075158" FT VARIANT 860 FT /note="R -> G (in LQT8; gain-of-function effect on channel FT activity)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075159" FT VARIANT 878 FT /note="S -> R (found in a clear cell renal carcinoma case; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064700" FT VARIANT 1135 FT /note="E -> K (in TS and BRGDA3; likely pathogenic; affects FT voltage-gated calcium channel activity resulting in loss of FT selectivity for Ca(2+) and other divalent cations over FT monovalent cations; mutant channels show a marked increase FT in sodium-mediated inward currents and potassium-mediated FT outward currents)" FT /evidence="ECO:0000269|PubMed:20817017, FT ECO:0000269|PubMed:30172029, ECO:0000269|PubMed:8099908" FT /id="VAR_087767" FT VARIANT 1159 FT /note="R -> H (found in a patient with autism; uncertain FT significance)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078701" FT VARIANT 1186 FT /note="I -> T (in TS and LQT8; likely pathogenic; FT gain-of-function shift to a more negative potential in the FT voltage-dependence of activation, leading to an increased FT window current and increased steady-state current; FT unchanged voltage-dependence of inactivation and FT inactivation velocity)" FT /evidence="ECO:0000269|PubMed:25260352, FT ECO:0000269|PubMed:25633834" FT /id="VAR_072381" FT VARIANT 1186 FT /note="I -> V (in LQT8; likely pathogenic; affects FT voltage-gated calcium channel activity resulting in FT increased peak current amplitude)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075160" FT VARIANT 1187 FT /note="V -> A (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087768" FT VARIANT 1365 FT /note="A -> T (in LQT8; uncertain significance)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075161" FT VARIANT 1408 FT /note="L -> V (in NEDHLSS; affects voltage-gated calcium FT channel activity resulting in decreased current density FT when expressed in a heterologous system)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087769" FT VARIANT 1411 FT /note="V -> L (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087770" FT VARIANT 1411 FT /note="V -> M (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:30513141" FT /id="VAR_087771" FT VARIANT 1523 FT /note="I -> M (in LQT8; likely pathogenic; gain-of-function FT shift to a more negative potential in the FT voltage-dependence of activation; increased steady-state FT current)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075162" FT VARIANT 1544 FT /note="E -> K (in LQT8; likely pathogenic; gain-of-function FT shift to a more negative potential in the FT voltage-dependence of activation; slower channel FT inactivation and increased steady-state current)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075163" FT VARIANT 1755 FT /note="V -> I" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075164" FT VARIANT 1765 FT /note="A -> G" FT /evidence="ECO:0000269|PubMed:20817017, FT ECO:0000269|PubMed:25633834" FT /id="VAR_075165" FT VARIANT 1787 FT /note="D -> N (in LQT8; uncertain significance)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075166" FT VARIANT 1800 FT /note="T -> I (in LQT8; uncertain significance)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075167" FT VARIANT 1831 FT /note="G -> C (in LQT8; uncertain significance; no effect FT on channel activity)" FT /evidence="ECO:0000269|PubMed:24728418" FT /id="VAR_075168" FT VARIANT 1835 FT /note="T -> M" FT /evidence="ECO:0000269|PubMed:20817017, FT ECO:0000269|PubMed:25633834" FT /id="VAR_075169" FT VARIANT 1843 FT /note="G -> R" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075170" FT VARIANT 1868 FT /note="P -> L (in dbSNP:rs10848683)" FT /id="VAR_059223" FT VARIANT 1869 FT /note="M -> V (in dbSNP:rs10774053)" FT /evidence="ECO:0000269|PubMed:1316612, FT ECO:0000269|PubMed:9087614, ECO:0000269|Ref.10" FT /id="VAR_059224" FT VARIANT 1893 FT /note="K -> R (in dbSNP:rs10774054)" FT /evidence="ECO:0000269|PubMed:1316612, FT ECO:0000269|PubMed:9087614, ECO:0000269|Ref.10" FT /id="VAR_061102" FT VARIANT 1916 FT /note="Q -> QEETSQ (in BRGDA3; uncertain significance)" FT /evidence="ECO:0000269|PubMed:20817017" FT /id="VAR_090202" FT VARIANT 1920 FT /note="Y -> C (in BRGDA3; uncertain significance)" FT /evidence="ECO:0000269|PubMed:20817017" FT /id="VAR_090203" FT VARIANT 1948 FT /note="E -> K (in LQT8; uncertain significance)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075171" FT VARIANT 1953 FT /note="T -> M (in LQT8; uncertain significance)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075172" FT VARIANT 1963 FT /note="R -> Q (in BRGDA3; likely benign)" FT /evidence="ECO:0000269|PubMed:20817017" FT /id="VAR_090204" FT VARIANT 1972 FT /note="R -> C" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075173" FT VARIANT 1989..2221 FT /note="Missing (in NEDHLSS)" FT /evidence="ECO:0000269|PubMed:34163037" FT /id="VAR_087772" FT VARIANT 1989 FT /note="R -> Q (in LQT8; uncertain significance)" FT /evidence="ECO:0000269|PubMed:23677916" FT /id="VAR_082635" FT VARIANT 2056 FT /note="R -> Q (in dbSNP:rs112414325)" FT /evidence="ECO:0000269|PubMed:20817017, FT ECO:0000269|PubMed:25633834" FT /id="VAR_075174" FT VARIANT 2081 FT /note="T -> N (in LQT8; uncertain significance; FT dbSNP:rs771424529)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075175" FT VARIANT 2091 FT /note="A -> S (found in a case of sudden unexplained death FT in the young; uncertain significance; results in increased FT whole-cell calcium currents)" FT /evidence="ECO:0000269|PubMed:27218670" FT /id="VAR_076415" FT VARIANT 2097 FT /note="V -> I (in LQT8 and BRGDA3; uncertain significance; FT affects channel activity resulting in reduced channel FT conductance and reduced peak current density; FT half-inactivation voltage is shifted to more negative FT potentials)" FT /evidence="ECO:0000269|PubMed:20817017, FT ECO:0000269|PubMed:25633834" FT /id="VAR_075176" FT VARIANT 2122 FT /note="A -> G (in LQT8; uncertain significance; FT dbSNP:rs549476254)" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075177" FT VARIANT 2169 FT /note="A -> T" FT /id="VAR_001496" FT VARIANT 2174 FT /note="N -> S" FT /evidence="ECO:0000269|PubMed:25633834" FT /id="VAR_075178" FT VARIANT 2213 FT /note="D -> N (in BRGDA3; uncertain significance)" FT /evidence="ECO:0000269|PubMed:20817017" FT /id="VAR_090205" FT MUTAGEN 363 FT /note="E->K: Loss of selectivity for divalent over FT monovalent cations." FT /evidence="ECO:0000269|PubMed:8099908" FT MUTAGEN 954 FT /note="G->F: Affects voltage-dependent inhibition by FT dihydropyridines; when associated with I-958." FT /evidence="ECO:0000269|PubMed:7737988" FT MUTAGEN 958 FT /note="Y->I: Affects voltage-dependent inhibition by FT dihydropyridines; when associated with F-954." FT /evidence="ECO:0000269|PubMed:7737988" FT MUTAGEN 1135 FT /note="E->Q: Decreased selectivity for divalent over FT monovalent cations." FT /evidence="ECO:0000269|PubMed:8099908" FT MUTAGEN 1464 FT /note="E->A: Decreased selectivity for divalent over FT monovalent cations." FT /evidence="ECO:0000269|PubMed:8099908" FT MUTAGEN 1610 FT /note="L->A: Loss of a low-affinity interaction with CALM1. FT No effect on channel inactivation by Ca(2+) and FT calmodulin." FT /evidence="ECO:0000269|PubMed:20953164" FT MUTAGEN 1666..1670 FT /note="FYATF->AAATA: Mildly decreased channel activity. No FT effect on channel inactivation. Loss of channel FT inactivation by Ca(2+) and calmodulin; when associated with FT A-1672." FT /evidence="ECO:0000269|PubMed:16299511" FT MUTAGEN 1672 FT /note="I->A: Loss of channel inactivation by Ca(2+) and FT calmodulin; when associated with 1666-A--A-1670." FT /evidence="ECO:0000269|PubMed:16299511" FT CONFLICT 1072 FT /note="K -> Q (in Ref. 3; Z26272)" FT /evidence="ECO:0000305" FT CONFLICT 1157 FT /note="N -> K (in Ref. 15; AAA58409)" FT /evidence="ECO:0000305" FT CONFLICT 1244 FT /note="L -> P (in Ref. 16; AAA74590)" FT /evidence="ECO:0000305" FT CONFLICT 1384 FT /note="L -> P (in Ref. 16; AAA74590)" FT /evidence="ECO:0000305" FT CONFLICT 1412 FT /note="A -> V (in Ref. 12; AAI46847)" FT /evidence="ECO:0000305" FT CONFLICT 1459 FT /note="R -> K (in Ref. 3; CAA81219)" FT /evidence="ECO:0000305" FT CONFLICT 2205 FT /note="R -> A (in Ref. 3; FT CAA84340/CAA84341/CAA84342/CAA84343/CAA84344/CAA84345/CAA84346/CAA84347/CAA84348/CAA84349/CAA84350/CAA84351, FT 7; CAA12174 and 9; AAX37354/AAX37355/AAX37356)" FT /evidence="ECO:0000305" FT CONFLICT 2205 FT /note="R -> G (in Ref. 1; AAA17030)" FT /evidence="ECO:0000305" FT HELIX 48..65 FT /evidence="ECO:0007829|PDB:2LQC" FT HELIX 113..116 FT /evidence="ECO:0007829|PDB:8FHS" FT TURN 119..122 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 126..142 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 148..150 FT /evidence="ECO:0007829|PDB:8WE8" FT HELIX 154..181 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 185..187 FT /evidence="ECO:0007829|PDB:8FD7" FT HELIX 194..216 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 233..236 FT /evidence="ECO:0007829|PDB:8WE7" FT HELIX 237..242 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 245..250 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 252..262 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 266..268 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 269..289 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 290..292 FT /evidence="ECO:0007829|PDB:8WE7" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 301..304 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 305..307 FT /evidence="ECO:0007829|PDB:8FD7" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 315..317 FT /evidence="ECO:0007829|PDB:8FD7" FT STRAND 321..323 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 327..329 FT /evidence="ECO:0007829|PDB:8FD7" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 339..342 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 344..348 FT /evidence="ECO:0007829|PDB:8WE8" FT HELIX 351..360 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 365..375 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 378..381 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 382..389 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 390..394 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 395..418 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 429..443 FT /evidence="ECO:0007829|PDB:5V2Q" FT TURN 444..446 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 510..513 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 514..521 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 522..524 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 528..541 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 552..576 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 580..585 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 587..607 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:8WE8" FT HELIX 617..630 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 635..646 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 648..673 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 674..676 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 680..683 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 689..691 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 692..704 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 705..707 FT /evidence="ECO:0007829|PDB:8WE9" FT HELIX 708..718 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 720..723 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 724..727 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 728..730 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 731..747 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 749..776 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 777..782 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 891..897 FT /evidence="ECO:0007829|PDB:8FD7" FT HELIX 900..902 FT /evidence="ECO:0007829|PDB:8WEA" FT HELIX 903..913 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 915..918 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 925..928 FT /evidence="ECO:0007829|PDB:8WE7" FT HELIX 929..933 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 954..974 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 977..981 FT /evidence="ECO:0007829|PDB:8FD7" FT HELIX 983..986 FT /evidence="ECO:0007829|PDB:8HMB" FT HELIX 990..1006 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 1010..1013 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1014..1017 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1020..1023 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1025..1028 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 1029..1031 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 1033..1036 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1037..1048 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 1049..1051 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1052..1071 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 1072..1074 FT /evidence="ECO:0007829|PDB:8WE9" FT STRAND 1077..1080 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1086..1088 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1091..1096 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1097..1099 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1103..1108 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1111..1113 FT /evidence="ECO:0007829|PDB:8WE8" FT HELIX 1121..1132 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1133..1136 FT /evidence="ECO:0007829|PDB:8EOI" FT HELIX 1137..1145 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 1149..1151 FT /evidence="ECO:0007829|PDB:8FD7" FT STRAND 1156..1158 FT /evidence="ECO:0007829|PDB:8FD7" FT HELIX 1160..1162 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1163..1169 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1170..1177 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1178..1194 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1195..1198 FT /evidence="ECO:0007829|PDB:8FD7" FT STRAND 1200..1202 FT /evidence="ECO:0007829|PDB:8WE9" FT HELIX 1206..1214 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1228..1236 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1239..1255 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1256..1259 FT /evidence="ECO:0007829|PDB:8FD7" FT HELIX 1265..1300 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1302..1321 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1330..1348 FT /evidence="ECO:0007829|PDB:8FD7" FT TURN 1371..1374 FT /evidence="ECO:0007829|PDB:8EOI" FT TURN 1375..1377 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1378..1381 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1383..1388 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1394..1407 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1411..1430 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1439..1445 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1447..1449 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1450..1461 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1466..1471 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1474..1477 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 1481..1483 FT /evidence="ECO:0007829|PDB:8WEA" FT STRAND 1489..1491 FT /evidence="ECO:0007829|PDB:8EOI" FT HELIX 1499..1524 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1527..1530 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1531..1533 FT /evidence="ECO:0007829|PDB:8EOI" FT HELIX 1534..1537 FT /evidence="ECO:0007829|PDB:8FD7" FT HELIX 1539..1550 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1554..1557 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1558..1560 FT /evidence="ECO:0007829|PDB:8EOI" FT HELIX 1562..1566 FT /evidence="ECO:0007829|PDB:8WE6" FT HELIX 1569..1571 FT /evidence="ECO:0007829|PDB:8WE6" FT TURN 1574..1576 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1579..1581 FT /evidence="ECO:0007829|PDB:8WEA" FT STRAND 1583..1585 FT /evidence="ECO:0007829|PDB:8WEA" FT HELIX 1586..1593 FT /evidence="ECO:0007829|PDB:8WE6" FT STRAND 1597..1599 FT /evidence="ECO:0007829|PDB:8WE9" FT STRAND 1601..1603 FT /evidence="ECO:0007829|PDB:8WE9" FT HELIX 1609..1651 FT /evidence="ECO:0007829|PDB:3G43" FT TURN 1654..1657 FT /evidence="ECO:0007829|PDB:8EOG" FT HELIX 1659..1661 FT /evidence="ECO:0007829|PDB:6U3B" FT HELIX 1666..1680 FT /evidence="ECO:0007829|PDB:2F3Y" FT HELIX 1973..1975 FT /evidence="ECO:0007829|PDB:8UKP" FT CONFLICT Q13936-26:1573 FT /note="A -> T (in Ref. 3; CAA84348)" FT /evidence="ECO:0000305" SQ SEQUENCE 2221 AA; 248977 MW; 7E755F7AF4C86769 CRC64; MVNENTRMYI PEENHQGSNY GSPRPAHANM NANAAAGLAP EHIPTPGAAL SWQAAIDAAR QAKLMGSAGN ATISTVSSTQ RKRQQYGKPK KQGSTTATRP PRALLCLTLK NPIRRACISI VEWKPFEIII LLTIFANCVA LAIYIPFPED DSNATNSNLE RVEYLFLIIF TVEAFLKVIA YGLLFHPNAY LRNGWNLLDF IIVVVGLFSA ILEQATKADG ANALGGKGAG FDVKALRAFR VLRPLRLVSG VPSLQVVLNS IIKAMVPLLH IALLVLFVII IYAIIGLELF MGKMHKTCYN QEGIADVPAE DDPSPCALET GHGRQCQNGT VCKPGWDGPK HGITNFDNFA FAMLTVFQCI TMEGWTDVLY WVNDAVGRDW PWIYFVTLII IGSFFVLNLV LGVLSGEFSK EREKAKARGD FQKLREKQQL EEDLKGYLDW ITQAEDIDPE NEDEGMDEEK PRNMSMPTSE TESVNTENVA GGDIEGENCG ARLAHRISKS KFSRYWRRWN RFCRRKCRAA VKSNVFYWLV IFLVFLNTLT IASEHYNQPN WLTEVQDTAN KALLALFTAE MLLKMYSLGL QAYFVSLFNR FDCFVVCGGI LETILVETKI MSPLGISVLR CVRLLRIFKI TRYWNSLSNL VASLLNSVRS IASLLLLLFL FIIIFSLLGM QLFGGKFNFD EMQTRRSTFD NFPQSLLTVF QILTGEDWNS VMYDGIMAYG GPSFPGMLVC IYFIILFICG NYILLNVFLA IAVDNLADAE SLTSAQKEEE EEKERKKLAR TASPEKKQEL VEKPAVGESK EEKIELKSIT ADGESPPATK INMDDLQPNE NEDKSPYPNP ETTGEEDEEE PEMPVGPRPR PLSELHLKEK AVPMPEASAF FIFSSNNRFR LQCHRIVNDT IFTNLILFFI LLSSISLAAE DPVQHTSFRN HILFYFDIVF TTIFTIEIAL KILGNADYVF TSIFTLEIIL KMTAYGAFLH KGSFCRNYFN ILDLLVVSVS LISFGIQSSA INVVKILRVL RVLRPLRAIN RAKGLKHVVQ CVFVAIRTIG NIVIVTTLLQ FMFACIGVQL FKGKLYTCSD SSKQTEAECK GNYITYKDGE VDHPIIQPRS WENSKFDFDN VLAAMMALFT VSTFEGWPEL LYRSIDSHTE DKGPIYNYRV EISIFFIIYI IIIAFFMMNI FVGFVIVTFQ EQGEQEYKNC ELDKNQRQCV EYALKARPLR RYIPKNQHQY KVWYVVNSTY FEYLMFVLIL LNTICLAMQH YGQSCLFKIA MNILNMLFTG LFTVEMILKL IAFKPKGYFS DPWNVFDFLI VIGSIIDVIL SETNHYFCDA WNTFDALIVV GSIVDIAITE VNPAEHTQCS PSMNAEENSR ISITFFRLFR VMRLVKLLSR GEGIRTLLWT FIKSFQALPY VALLIVMLFF IYAVIGMQVF GKIALNDTTE INRNNNFQTF PQAVLLLFRC ATGEAWQDIM LACMPGKKCA PESEPSNSTE GETPCGSSFA VFYFISFYML CAFLIINLFV AVIMDNFDYL TRDWSILGPH HLDEFKRIWA EYDPEAKGRI KHLDVVTLLR RIQPPLGFGK LCPHRVACKR LVSMNMPLNS DGTVMFNATL FALVRTALRI KTEGNLEQAN EELRAIIKKI WKRTSMKLLD QVVPPAGDDE VTVGKFYATF LIQEYFRKFK KRKEQGLVGK PSQRNALSLQ AGLRTLHDIG PEIRRAISGD LTAEEELDKA MKEAVSAASE DDIFRRAGGL FGNHVSYYQS DGRSAFPQTF TTQRPLHINK AGSSQGDTES PSHEKLVDST FTPSSYSSTG SNANINNANN TALGRLPRPA GYPSTVSTVE GHGPPLSPAI RVQEVAWKLS SNRERHVPMC EDLELRRDSG SAGTQAHCLL LRKANPSRCH SRESQAAMAG QEETSQDETY EVKMNHDTEA CSEPSLLSTE MLSYQDDENR QLTLPEEDKR DIRQSPKRGF LRSASLGRRA SFHLECLKRQ KDRGGDISQK TVLPLHLVHH QALAVAGLSP LLQRSHSPAS FPRPFATPPA TPGSRGWPPQ PVPTLRLEGV ESSEKLNSSF PSIHCGSWAE TTPGGGGSSA ARRVRPVSLM VPSQAGAPGR QFHGSASSLV EAVLISEGLG QFAQDPKFIE VTTQELADAC DMTIEEMESA ADNILSGGAP QSPNGALLPF VNCRDAGQDR AGGEEDAGCV RARGRPSEEE LQDSRVYVSS L //